MIT Holding, Inc. (fka MITD)

[5%PerDayCompounded]

Any shareholders out there?

[Renee]

MITD revoked:

https://www.sec.gov/litigation/admin/2016/34-78335.pdf

[Renee]

MITD SEC Suspension: The Commission temporarily suspended trading in the securities of Mit Holding, Inc. due to a lack of current and accurate information about the company because it has not filed certain
periodic reports with the Commission and also filed certain reports with financial statements that were not audited and/or reviewed by an auditor as required by Commission rules. This order was entered pursuant to Section 12(k) of the Securities Exchange Act of 1934 (Exchange Act)

https://www.sec.gov/litigation/suspensions/2016/34-78067.pdf

Order:

https://www.sec.gov/litigation/suspensions/2016/34-78067-o.pdf

Admin Proceeding:

https://www.sec.gov/litigation/admin/2016/34-78068.pdf

[sidedraft]

Ouch!

On October 5, 2015, the Board of Directors of MIT Holding, Inc. (the “Company”) determined that the Company’s previously issued unaudited and unreviewed consolidated financial statements for the periods from March 31, 2011 to June 30, 2015 should no longer be relied upon.
http://ih.advfn.com/p.php?pid=nmona&article=68986485&symbol=MITD

[chadsm]

Beware ..Turd stock.

[QualityStocks]

MITD Industry-Changing Solutions Address Key Post-Care Concerns

You could assume plenty of reasons someone may not be a fan of going to the hospital. Fears of doctors, needles and tests aside, many people simply cringe at the aftermath of a hospital: recovery and bill management.

MIT Holding provides professional outpatient medical care with ambulatory infusion therapies, home infusion services and medical equipment delivery. At the core of its operations, MIT Holding is addressing the mayhem associated with hospital discharge and subsequent at-home recovery, working through its growing network of accredited agents, facilitators and contractual obligations to operate as a single-source provider of the aforementioned services.

From the time of patient discharge from the medical facility, MITD handles everything pertaining to the at-home recovery phase, including in-home medical equipment, infusion services, medications, follow-up appointments, organize therapy sessions, wound dressings, transportation. This saves the patient and their caretakers with significant convenience and assistance through what might otherwise become a burdensome task that delays full recovery.

MITD’s goal here is to make sure there is no lapse in patient care or communication. Furthermore, the digital paperwork MIT maintains in order to monitor the patient’s recovery contains all the information the hospital and doctors need to comply with the industry rules.

Another advantage is that MITD meets and/or exceeds major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators. This ability marks an important step in the company’s goal of developing the first-of-its-kind seamless transition for patient needs from hospital discharge to complete home recovery. Because the company handles insurance inquires and professional insurance claim billing, mounting claims, bills and calls to insurance companies are no longer an insurmountable task.

The company also provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Revolutionary to the broader healthcare industry, MITD’s sails are starting to catch wind as it sees the fruition of its reorganization strategy implemented in 2014. The company last month reported that sales for the first six months were $851,724, an increase over sales of $473,153 for the same period of 2014. Adjusted net income for the period was $265,967, or $0.0027 per diluted share. In a GAAP basis, MITD’s first six months of 2015 earned a gross profit of $631,725 compared to $312,240 for the comparable period of 2014.

For the six-month period ended June 30, 2015, MITD produced a per share profit on 202% increase in revenues, as compared to the same period of 2014, reflecting a 37% increase in receivables.

“We are pleased with the strong financial and operational performance of our reorganization strategy. The first six months of profit and growth validate our strategy and approach to our business model,” MITD Chief Executive Officer Walter Drakeford stated in a previous news release. “The unabated growth in the medical industry is creating headwinds, contributing to our continued growth and profitability. The MITD concept of bringing together all necessary services and products under one umbrella for a patient’s post-medical event recovery is, to our knowledge, the first in the industry.”

For more information, visit http://mitholdinginc.com

[QualityStocks]

MITD Prepared to Build on Profitable Results through National Expansion Efforts

Since implementing its updated corporate goals at the beginning of 2014, MIT Holding, Inc. has made tremendous progress toward capitalizing on the steady growth of the medical industry. In the second quarter of 2015, this progress materialized into the first profitable quarter in the company’s history, as well as an 80 percent year-over-year increase in total sales. With profitability achieved, MITD is now firmly focused on promoting national expansion through both organic growth and strategic acquisitions. Through these efforts, the company will look to continue refining its first-of-its-kind, comprehensive recovery concept, which facilitates and assists patients from the time of their release from a hospital through to a full in-home recovery.

“The first six months of profit and growth validate our strategy and approach to our business model,” Walter Drakeford, chief executive officer of MITD, stated in a news release. “The unabated growth in the medical industry is creating headwinds, contributing to our continued growth and profitability.”

MITD is also benefitting from the medical industry’s ongoing shift toward value-based purchasing options. Rather than continuing to reward healthcare providers based solely on volume of care delivered, the U.S. Department of Health and Human Services (HHS) has recently pushed for a move toward less expensive, value-based care. In 2014, an estimated 20 percent of Medicare reimbursements had shifted away from volume-based payment frameworks, and HHS has set a goal to have 85 percent of Medicare fee-for-service payments in value-based purchasing categories by 2016.

As a result of this market shift, the United States home infusion market is expected to achieve steady growth moving forward, climbing at a compound annual growth rate of just over 9 percent through 2020. According to a report by Harris Williams & Co., home or alternate site home infusion services present patients with a dramatic 90 percent daily cost savings as compared to receiving the same services in a traditional hospital setting.

With its first quarter of profitability now in the books and an established expansion plan in place, MITD is in a favorable position to capitalize on the pivot toward value-based care options while continuing to promote market growth. Look for the company to lean on the marketability of its comprehensive recovery concept, as well as the strong performance of the medical industry, in order to promote sustainable returns.

For more information on MIT Holding, visit http://mitholdinginc.com/

[QualityStocks]

MITD – Moves From Re-Org to Acquisition Phase

The steady growth of the medical industry is creating ripples, contributing to the sustained growth and profitability that healthcare companies like MIT Holding (OTC: MITD) are experiencing. Following the initiation of reorganization with several strategic initiatives in 2014, MIT Holding has established profitability and is set to achieve positive net profits for this year. The evidenced profitability substantiates the company’s business model, as well as its approach to the developing Affordable Health Care Act (a.k.a. Obamacare) and its resulting impact on the health services industry.

MIT Holding has worked at implementing its first-in-the-industry concept of bringing together, under one umbrella, all of the services and products needed for a patient’s post-medical event recovery. Through agents, facilitators and contractual obligations, the company has ensured that it can provide expert outpatient medical care via ambulatory infusion therapies, home infusion services and medical equipment delivery.

This umbrella of services will allow MIT Holding to make an acquisition of a local pharmacy, clinic, lab or other targeted medical facility, with “overnight” incentives to the owners. For example with MIT Holdings direct billing ability to over a hundred insurance carriers, an acquisition can immediately begin offering additional products and services they had neglected in the past do to inability to bill and receive payment for those services. MIT Holding will free up owners and personal from hours of weekly billing hassles, so they can dedicate 100% of their efforts to core growth.

One of the reasons for the current corporate structure of MIT Holding was to take the burden of administration off of the local facility. This gives the employees the ability to offer superior care and attention to the patient, which in turn echoes up the “referral food chain” families, doctors and hospitals, who in turn refer additional patients to the MIT Holding system.

The patient’s prescriptions, doctors, hospitals and medical needs will constantly change throughout their lives. MIT Holding will always be there. The patient has one constant they can count on through simple and difficult medical events, MIT Holding.

To support its core services, MIT Holding also:

– offers professional accounting, advisory, legal and educational services to physicians, medical centers, hospitals and small and large businesses regarding the Affordable Care Act (a.k.a. Obamacare) and Meaningful Use Rules (MUR);

– provides travel and transportation services to medically-challenged patients with medical needs or in need of personal travel; and

– conducts and administers FDA clinical trials that have been approved through its contracts.

Operationally, MIT Holding meets and or, exceeds major U.S. health insurance requirements so it is able to bill and receive payments directly from the carriers, on behalf of patients. This capability is particularly significant to the company’s mission of developing a profitable first-of-its-kind seamless transition for patients, from their hospital bed discharge to their complete home recovery.

For more information, visit http://mitholdinginc.com

[QualityStocks]

MITD Posts First Quarter of Profitability in Company History

MIT Holding, a Los Angeles-based company operating through its network of agents, facilitators and contractual obligations to offer professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery, this morning reported its financial results for the 2015 second quarter, marking the company’s first quarter of profitability.

Key points include:

• MITD’s sales for the first six months were $851,724, an increase over sales of $473,153 for the same period of 2014. Adjusted net income for the period was $265,967, or $0.0027 per diluted share.
• On a GAAP basis, MITD’s first six months of 2015 earned a gross profit of $631,725 compared to $312,240 for the comparable period of 2014.
• Receivables increased to $286,853 as compared to $208,269 for the same period of 2014.
• The six-month period ended June 30, 2015, produced a per share profit on 202% increase in revenues, as compared to the same period of 2014, reflecting a 37% increase in receivables.
• MITD is currently in the process of completing corporate audits to become fully compliant with the SEC by year-end 2015.

“After implementing our corporate goals on January 1, 2014, we experienced normal growing pains and produced a profitable and solid company in 18 months. The business plan is now firmly entrenched in the expansion phase. In addition to organic growth goals of 20-25% per year on existing business, we expect acquisitions and the opening of new facilities in untapped geographic locations throughout the United States. When we cannot locate a sound acquisition for purchase within a target market, MIT Holding has the ability to ‘open from scratch’ facilities that will host our products and services,” Tommy Duncan, president of MIT Holding, stated in the news release.

MIT Holding Chief Executive Officer Walter Drakeford commented on industry challenges and the company’s unique position in the medical market.

“We are pleased with the strong financial and operational performance of our reorganization strategy. The first six months of profit and growth validate our strategy and approach to our business model. The unabated growth in the medical industry is creating headwinds, contributing to our continued growth and profitability. The MITD concept of bringing together all necessary services and products under one umbrella for a patient’s post-medical event recovery is, to our knowledge, the first in the industry,” he stated.

The company also announced it will hold an upcoming investors conference call prior to the end of third quarter September 30, 2015. Date, time and dial-in instructions will be released two weeks prior to the call.

For more information visit http://mitholdinginc.com/

[QualityStocks]

MITD - Identifies Industry Transition to Value-Based & Ambulatory Care; Moves to Profitability as a Result

The continued growth of the ambulatory (outpatient) care market is driven by a number of emergent factors. The increase in life spans have incubated a prevalence of diseases such as diabetes and COPD (chronic obstructive pulmonary disease) among an increasingly elderly population of retiring Baby Boomers. Insurance carriers are now authorizing payments for more services that that result in more affordable convenience and logistical efficacy of home-based recuperation for these patients, with cost savings of up to 65 percent for minimally invasive procedures when performed at home or in an ambulatory care center. However, it is extremely difficult for already overburdened families to successfully arrange and utilize a comprehensive suite of services, such as home-based infusions, access to durable medical equipment (DME), and the benefits of a comprehensive prescription drug program administrated by a pharmacy benefit manager, by a single healthcare provider (PBM).

MIT Holding Inc. (OTC: MITD) has identified this niche and filled it successfully. Moreover, all participants in the ambulatory care market, whether patients, medical facilities or insurance carriers, benefit directly from tight-knit relationships and the kind of well-oiled networking machinery that MIT Holding offers its patients.

This is particularly important as the industry continues rapidly transitioning from Meaningful Use Stage 1 requirements to the much more complex criteria of Stage 2, where robust clinical reporting that is in-line with regulatory and quality-driven initiatives, as well as coordinated care and patient engagement, are paramount. When it comes to Medicare and Medicaid EHR (electronic health record) Incentive Program participation, healthcare information technology (HCIT) continues to open new doors for the ambulatory care market, and this segment of the overall healthcare market stands to deliver optimum results when it comes to the prevailing value-based care initiatives as well. Patient long-term outcomes and customer service are more of a key focus in ambulatory care than in acute hospital care, and this is a major driving factor of the industry’s continued shift toward ambulatory care.

Organized as a single source provider for a wide range of services and products to patients through its network of affiliates and contractors, MIT Holding is able to hit the sweet spot between cost effective care and customer service. The company delivers intravenous infusions for home and ambulatory care center injection via its full service compounding pharmacy, as well as pharmaceuticals, medical equipment for the home, and other home-based healthcare. The typical high cost of specialized infusion pharmacy services can be substantially ameliorated through ambulatory care, and the kind of customized education/counseling that is also required to get the patient situated regarding their condition and the requisite treatments, is ideally deliverable via the ambulatory care model (again in clear contrast with hospital care).

Saving the patient time and money is also a highly lucrative niche market for MIT Holding, as infusion medications typically require preparation by highly specialized pharmacy operations employing registered pharmacists, and the therapy itself is generally administered by a registered nurse or trained caregiver that ideally has established a good, long-term relationship with the patient.

A growing number of therapies are now deliverable in this fashion as well, making in-home treatment increasingly attractive to patients, and the option of going to a contracted ambulatory care center (the company operates one itself), staffed with full-time nurses and a doctor, in order to receive improved consultation, or assistance in obtaining reimbursement, is seen as a huge advantage to many patients and their families.

This is a big, growing market for MIT Holding, spanning such infusion therapies as total parenteral nutrition for chronic digestive and gastro-intestinal disorders, anti-ineffective therapies for diseases like chronic urinary tract infections, chronic pain management through intravenous or continuous analgesics, and a variety of others. In this same vein, the company’s DME sales and leasing capabilities, with access to a host of devices ranging from wheelchairs and oxygen concentrators, to nebulizers and other sustained-use equipment, provides MIT Holding with a constantly growing amount of Medicaid billing.

The expansion last year of the DME contract by WellPoint’s (NYSE: WLP) Georgia subsidiary, Amerigroup Community Care, to cover all of MIT Holding’s services (including ambulatory, infusion and perinatal), is a prime example of the company’s continually growing post-acute network footprint. Similarly, two contracts awarded more recently by HCIT and post-acute treatment patient transition innovator Curaspan Health Group, which maintains an impressive 98 percent customer retention rate, gave the company real-time access to market its compound pharmaceuticals, infusion services and DME offerings to the patients of over 5,400 Curaspan driven medical facilities nationwide.

The company’s deal with Coastal Carolina Medical Center is another good example here, in that the in-patient treatments MIT Holding was initially engaged to do dovetail exceptionally well with subsequent, more expansive ambulatory care service provisions, generating billing in the $1,000 per treatment range for the company.

With current approval by more than 130 insurance carriers for a variety of medical goods and services, as well as a much more focused core of operations specifically in the home health recovery space, MIT Holding has seriously tightened up its cost and revenue structure subsequent to its reorganization that began in 2011, and currently enjoys a 32 percent net profit standard on sales, services, and the like moving forward. Estimates of up to 90 percent savings for patients who utilize in-home infusion services will continue to be a major contributor to the company’s success, and with the U.S. home infusion market on track to grow 68 percent over the next five years to around $26.7 billion, MIT Holding will be looking to carve an ever-increasing slice of that pie off for its shareholders in years to come.

A continued focus on providing affordable, customer service-driven delivery of high-cost, low volume specialty infusions spells big profit for MIT Holding, and the requisite handling/administration requirements associated with such infusions will help the company maintain a firm grasp on the underlying market’s dynamics. And because MIT Holding handles all its own billing and collection practices via a sophisticated computerized billing framework, obtaining the lion’s share of its revenues from contracts with third party payers, affiliates and contractors, as well as self-pay patients and self-insured employers, the company has unprecedented fluidity when it comes to the claim review and editing process, as well as granular pre-service initiation control driven by rigorous insurance coverage verification and carrier authorization protocols.

For more information visit http://mitholdinginc.com/

[QualityStocks]

MITD – A Concierge Medical Service Provider Primed for Home Infusion Market

MIT Holding is a single source provider of concierge medical services and products throughout the United States. Through a portfolio of license, contractual and affiliate agreements, the company offers a portfolio of services that includes but is in no way limited to the:

• Administering of intravenous infusions;
• Management of medical services; and
• Provision of in-home therapies.

In a press release dated April 27, 2015, the company revealed that it had achieved positive net income from its operations in 2014, to the tune of over $14,000. This profit amount signaled significant improvement from the previous year’s numbers. It’s also a direct consequence of the company’s renewed focus on its in-home health recovery business and the resulting growth in overall income generated in 2014 (over $1.1 million).

Many aspects of the structure of MIT Holding’s in-home health recovery business, which facilitates and assists patients from the time of their release from a hospital through to a full in-home recovery, were finalized in 2014. The target audience for the business have been determined to be those needing infusion for recovery.

With many infusion therapies costing more than $10,000 per patient, per year and many patients needing special counseling and education regarding their condition and treatment, there is certainly a market for the business.
The two most recognized names in the infusion sector, CVS Health Corp. (NYSE: CVS) and Walgreen Co. (NYSE: WAG), have established footprints into the home infusion market through a series of strategic acquisitions that highlight the growing demand for home infusion services. The usual retail pharmacies and traditional distributors are generally designed to carry inventories of low cost, high volume products, while MIT Holding’s platform is based on the delivery of high cost, low volume specialty pharmaceuticals that have specialized handling and administration requirements.

Today’s United States home infusion market has been estimated at around $16 billion and is forecasted to reach approximately $27 billion by 2020, according to Harris Williams & Co. At a compound annual growth rate of approximately 9% per year, this could mean a significant market opportunity for MIT Holding. Furthermore, the company is anticipating that the demand for low cost, high quality home care will increase as paying patients become aware that they could realize up to 90% in savings on infusion services performed in the home versus in the hospital and that, as a result, this will result in continued growth for its in-home health recovery business. It is little wonder that this is an area of significant focus in its operations.

For more information, visit the company’s website at www.mitholdinginc.com

[QualityStocks]

MITD Offering High Quality Care at Reduced Costs through Home-Based Recovery Options

MIT Holding specializes in providing value-based healthcare options anchored by a commitment to strong customer service, excellent quality of care and improved quality of life for patients. In particular, the company is a trusted provider of home-based infusion services, enabling access to an expansive medical market. According to a report by Harris Williams & Co., the United States home infusion market is currently valued at $15.9 billion and is expected to grow to $26.7 billion within the next five years. This market growth is projected to come as payers continue to recognize the significant financial benefits of performing infusion services in the home, which can provide as much as 90 percent savings over those performed in a hospital setting.

“Our in-home health recovery business, which facilitates and assists patients from the time of their release from a hospital through to a full in-home recovery, is now in place,” Tommy Duncan, president of MITD, stated in a news release. “Our target audience is focused on those needing infusion for recovery.”

Currently, a large population of the potential home infusion market is being forced to visit hospitals in order to receive vital care. This is because of outdated Medicare guidelines that block payment for infusion drug patients that are treated at home. As a result, some patients are forced to endure daily hospital visits, costing the government an extra $585 million, according to the Department of Health and Human Services. However, these issues could be nearing a resolution.

In January, the Obama Administration announced plans to transition more than $100 billion in annual Medicare costs into value-based contracts designed to curb spending growth without reducing quality of care. This plan could be great news for MITD, as the company continues to realize strong market growth within the national healthcare industry. In 2014, MITD demonstrated its growth potential as it recorded an increase of more than $1.1 million in net income from operations.

As the national healthcare industry continues its shift toward value-based care, MITD is in a strong strategic position to promote sustainable growth moving forward. For prospective shareholders, the company’s proven home care services could provide a platform for favorable returns in the months to come.

For more information on MIT Holding, visit www.mitholdinginc.com

[QualityStocks]

MITD Filling Unmet Medical Needs with Direction from Experienced Management

Thanks to advances in medicine and technology, people are living much longer these days. For many people, this longevity creates an increasing need for proficient at-home care for the highest quality of life, as well as for full recovery following discharge from a medical facility. Selecting a healthcare provider specializing in home-based services can be troublesome and place heavy burden on patients and families. MIT Holding has a simple solution powered by a forward-thinking, visionary management team.

MIT Holding is a single source of high-quality, low cost need-fulfillment for patients provided during their at-home recovery. The company works through its growing network of accredited agents, facilitators and contractual obligations to operate as a single-source provider of professional outpatient medical care including pharmaceuticals, intravenous infusions, medical management services, and in-home or ambulatory center therapies, in addition to home medical equipment for sale or for rent.

The company also provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Furthermore, as an accredited healthcare provider, MIT is in full compliance with major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators.

Spearheading this first-of-its-kind business model is a management team of qualified individuals with a shared vision to keep the company at the front-edge of in-home services.

Walter H.C. Drakeford, MIT Holding’s chairman of the board of directors and chief executive officer, has a stellar career that includes the senior managing director of Drakeford & Drakeford for the past 20 years. Since 2007, he has been the director of mergers and acquisitions of AMC Global Communications, Inc. He has also served as chairman of the board for Ebank Financial Services, and has served on the boards of Netstar-USA Corp. and LaidLaw Transportation. Drakeford also served as an attache to the White House under former presidents Nixon, Reagan and George H.W. Bush.

CEO Drakeford began his career with a finance degree from the University of Berlin and a Masters of Business Administration from Heed University, as well as a law degree from Thomas Jefferson School of Law.

Company CFO Robert Yates in 2008 joined MIT Holding as controller. Since 1987, Yates has served as controller or chief financial officer in small-to-medium size firms in Northern California. He received his accounting degree from San Jose State University in 1978 and gained his accounting and auditing experience with Arthur Young & Co. in San Jose, California. Yates obtained his license as a Certified Public Accountant in 1980, and is a veteran who served in the U.S. Air Force in the Vietnam era.

Tommy J. Duncan, president of MIT Holding, became a member of the company’s board of directors in May 2007, and joined the board of directors of Medical Infusion Group in September 2006. Duncan is employed with Southeast Vending, LLC, where he has been president since 2001. He has also been president of Southeast Lumber and Construction, Inc. since 2001.

MIT Holding believes that Duncan has the experience, qualifications, attributes and skills necessary to serve on the board because of his experience in finance, his having provided leadership and strategic direction and knowledge of the company and its business.

Together, this team of professionals has introduced to the healthcare market a much-needed and first-of-its-kind business model that adheres to the changes of the Affordable Care Act and provides patients with unparalleled in-home recovery services.

For more information visit www.mitholdinginc.com

[QualityStocks]

MITD Benefits from Requirements of Documentation and Value-Based Healthcare Options

The healthcare industry is in the midst of a substantial shift away from traditional fee-for-service payments, which have historically been associated with excessive and unnecessary care, in favor of value-based options. In January, the Centers for Medicare and Medicaid Services reaffirmed this fact when it announced a goal of having 50 percent of all Medicare payments in alternative payment models by the end of 2018. MIT Holding, Inc. (OTCQB: MITD), a leading provider of post-acute care nationwide, is in a strong position to capitalize on this evolving mindset by providing ambulatory care, in-home intravenous therapies, medical equipment and other recovery needs to help patients avoid unnecessary doctor and hospital visits.

According to a report by Fox Business, the total reduction in overall healthcare spending as a result of ambulatory surgery and therapy options amounts to approximately $2.6 billion annually, and an additional $2.4 billion in savings could be realized if just 50 percent of eligible cases were moved to these non-hospital settings. For MITD, these potential savings could translate into improved financial returns in the coming months. Demand for the company’s low cost, high quality home care is expected to rise as payers realize up to 90 percent savings on infusion services performed in the home instead of the hospital.

The potential market for MITD’s home infusion services is vast. According to Harris Williams & Co., the United States home infusion market is currently valued at $15.9 billion, and continued growth is expected to push the market to $26.7 billion by 2020. In the first quarter of 2015, the company made significant strides toward maximizing its share of this pivotal sector by recording just under $490,000 in consolidated revenues, which was a year-over-year increase of over 133 percent. Leveraging an increase in referrals and the strategic use of subcontractors, MITD also realized a gross profit of nearly $278,000 for the period.

“Our target audience is focused on those needing infusion for recovery,” Tommy Duncan, president of MITD, stated in a news release. “Our platform is based on the delivery of these high cost, specialty pharmaceuticals that have specialized handling and administration requirements.”

For prospective investors, MITD’s strong financial results in recent quarters, as well as the increasing demand for its value-based services, could provide the company with a platform to deliver strong returns moving forward. Look for MITD to continue building on its established position within the ambulatory care market in order to capitalize on rising demand in the years to come.

For more information on MIT Holding, visit www.mitholdinginc.com

[QualityStocks]

MITD Single-Source Outpatient Care Model Driven by Cost-Effective Services, Custom Pharmaceuticals, Medical Supplies

The continually evolving healthcare market presents significant challenges for sector operators; not only when it comes to complying with the latest regulatory demands, but the complex logistical realities of patient care as well. MIT Holding (OTC: MITD) has assembled a unique mix of offerings that allows it to act, via a growing portfolio of contractual and affiliate agreements, as well as key licenses, in the role of a single-source provider to a variety of outpatient service and other markets. One of the most important relationships established by the company is with the originator of automated, on-demand online referral packets, Curaspan Health Group. Curaspan, a recognized Health Information Exchange and Patient Transition software company that helps connect providers, payers and suppliers through secure patient-transition network technologies and assists patients through their transition between different phases of care, is an important ally for MIT Holding’s ability to deliver winning solutions across the aforementioned markets, which are rapidly expanding as more and more people realize the benefits of outpatient care.

Markets like in-home infusion therapy, or the administration of medication through (typically) injection or catheter, is one of the top service areas enabled by MIT Holding’s contract with Curaspan. In-home infusion therapy has proven to be as safe and effective as inpatient care across for many diseases, is more convenient and comfortable for the patient, and generally results in better care and patient outcomes.

The contract provides MIT Holding access to a real-time market consisting of the patients from over 5,400 Curaspan affiliated medical facilities. By sending out a registered nurse to consult with the patient, conduct the administration of infusion care, help establish the patient’s medication and equipment needs in greater detail, as well as make determinations about any follow up appointments, additional therapy, or billing and insurance, MIT Holding is able to establish tightly-knit relationships and a stable commercial footprint.

Furthermore, MIT Holding – which specializes in providing an entire menu of such in-home recovery services and even operates ambulatory centers in Georgia through its subsidiaries – liaises directly with customers and is able to establish meaningful contact before the patient even leaves the healthcare facility. This personal contact allows the MIT Holding representative to map out a comprehensive home recovery template tailored to the individual.

With direct contact and MIT Holding’s tailored approach, outpatient care becomes an easy option for the end user, even before the cost savings over staying in the hospital have entered the equation.

The in-home infusion segment of the outpatient market alone is headed steadily upward from the $15.9 billion seen last year and is expected to reach a global market of over $26.7 billion within just the next five years (Persistence Market Research), growing at a CAGR of around 9.0 percent on the strength of increasingly aged populations around the globe, and increasing incident rates of chronic diseases which require infusion therapy.

This is particularly true in North America and Europe, infusion therapy’s two largest markets, where antibiotics and anti-infective indications represent the mainstay for major sector players like Baxter (NYSE: BAX) and CareFusion (NYSE: CFN), and are set to outpace the underlying infusion therapy market by around 0.8 percent CAGR over the same interval.

By 2050, 19 percent of the U.S. population will be over the age of 65; the incidence rate of chronic conditions is expected to follow suit, with estimates that over 170 million Americans will suffer some form of chronic disease by as early as 2030 (Harris Williams & Co.).

At the same time, the Patient Protection and Affordable Care Act (ACA) will continue to bring huge numbers of previously uninsured patients into the market. With nearly 11.7 million of the previously forecast 32 million uninsured set to be covered under the ACA already added to the rolls in state and federal marketplaces as of March 2015, according to Health and Human Services Secretary Sylvia Mathews Burwell, we are already starting to see the leading edge of this massive trend. The implications for outpatient care could be enormous.

For an in-home comprehensive health recovery services company like MIT Holding, this underlying phenomenology will continue to be a growth driver for many years to come, undergirding the company’s business model with a firm foundation that will only increasingly seek out the convenience and savings benefits its service offerings can provide. Taking care of the patient’s needs from hospital discharge through to recovery, and yet being able to provide as much as a 90 percent savings over equivalent care if it took place in a hospital setting, is a key factor that will continue to fuel MIT Holding’s revenue fire, helping the company extend the success of a profitable 2014. First quarter 2015 revenues were double that of the year prior.

The company also rents and sells robust medical equipment for the home, a market on track to hit $12.6 billion by 2018 in the U.S. alone, according to a study published last year by market analysts Freedonia, growing at a CAGR of 8.2 percent from the roughly $8.5 billion seen last year. The increase in chronic diseases like cancer, kidney failure and respiratory disorders will be a major contributing factor to rising demand for hardware like oxygen concentrators needed for COPD (chronic obstructive pulmonary disease) and the like.

Another key advantage MIT Holding has is access to specialty drugs and custom compound pharmaceuticals, allowing the company to cost effectively address the medicinal needs of its patient customers and offer compelling availability/affordability advantages. With the specialty pharmaceuticals market at over $78 billion last year (Drug Channels Institute), MIT Holding is in a prime position to compete with the 250 plus URAC-accredited (Utilization Review Accreditation Commission) specialty pharmacies out there (including about 100 “In Process” companies expected to achieve accreditation this year), possessing an established customer pool that is built on comprehensive services and face-to-face contact. The company also distributes wholesale pharmaceuticals in the U.S. and overseas via its subsidiaries.

With MIT Holding and its affiliates now able to direct bill and receive payments from over 138 of the country’s top regional and national carriers on behalf of patients, carriers like Medicare/Medicaid, as well as major players like Aetna (NYSE: AET) and Cigna (NYSE: CI), the company is now more confident than ever about its business model. The company leverages a model built on the medical and financial benefits of a smooth patient transition that takes them all the way through from their discharge at the hospital to recovery within the comfort and familiarity of their own home.

Learn more by visiting the company’s newly overhauled website at www.mitholdinginc.com

[QualityStocks]

MITD Offers Unique In-home Infusion Experiences Utilizing Fully Licensed Compounding Pharmaceuticals

Los Angeles-based MIT Holding has an established working arrangement with one of the approximately 400 compounding licensed pharmacies remaining in the United States. Currently, many big name pharmaceutical companies are buying up these compounding pharmacies to eliminate competition. However, MIT Holding has a contractual arrangement with a well-respected and highly qualified compounding pharmacy that enables it to fulfill its own infusion and other specialty prescriptions. This capability provides MIT Holding with a distinct advantage over local “mom-and-pop” infusion centers in the rapidly growing $11 billion a year U.S. infusion therapy market.

The two most recognized names in the infusion sector are CVS Health Corp. (NYSE: CVS) and Walgreen Co. (NYSE: WAG). Both of which have established footprints into the home infusion market through a series of strategic acquisitions that highlight the growing demand for home infusion services.

CVS earlier this year completed its acquisition of Coram LLC, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc., and in May entered into a definitive agreement to acquire Omnicare (NYSE: OCR). The acquisition of Omnicare is expected to greatly expand CVS’s specialty pharmacy business and increase its ability to dispense prescriptions in assisted living and long-term care facilities.

MIT Holding is also uniquely positioned to opportunities in the prescription dispensary and in-home infusion services markets. That is because MIT Holding’s business model is built around the company’s full suite of in-home recovery services, which begins when MIT Holding sends a company representative to a patient’s hospital bed on the day of discharge to establish a blueprint for successful home recovery.

Following the initial contact, MIT Holding will send a registered nurse (RN) directly to the patient’s home to provide infusion therapies and consultation. The typical four-hour infusion procedure allows the RN to establish a personal working rapport and customized recovery regimen for the patient, while cross-marketing MIT Holding’s complete suite of services. The RN offers a thorough analysis of the patient’s needs, from medications, durable medical equipment, doctor appointments, therapy sessions, insurance billing, insurance inquires, and a financial overview of the expected expenses of the remaining recovery period.

With current MIT Holding patients, this cross marketing approach is effective by including all other household members. MIT Holding benefits with an immediate expansion of its patient base by offering its services to meet the medical needs of these family members. Results have shown that families and patients often realize valuable savings on their medications, including the original infusion therapies.

MIT Holding’s new approach establishes a digital databank of information on the patient’s recovery regimen, which was created at the bedside of the patient at the point of discharge. This creates a new revenue stream of vital records necessary for doctors and hospitals to comply with new mandatory federal requirements, documenting their patient’s recovery.

Through its innovative and comprehensive in-home recovery services, which include specialty drugs, infusion services, compounding pharmaceuticals, direct insurance inquiries, insurance billing, and cross marketing efforts, MIT Holdings is in prime position to take advantage of multi-billion dollar markets. Based on IMS Health data, the specialty pharmaceuticals market is valued at $77.5 billion, constituting roughly a quarter of the overall market and growing at more than double (8.8%) the rate. Combined with the $11 billion home infusion market, these sectors are rapidly approaching the $100 billion mark.

For more information visit www.mitholding.com or contact William Nalley at 305-515-8077

[QualityStocks]

MITD Unique Healthcare Solution Solves Some of the Industry’s Greatest Challenges

The Health Information Technology for Economic and Clinical Health Act (HITECH) of 2009 establishes programs under Medicare and Medicaid to provide incentive payments for the use of certified electronic health records technology. Though these Meaningful Use Rules (MUR) were designed to improve healthcare outcomes by utilizing Electronic Health Records (ERH) and documentation, there’s an ugly side of the program that has left many healthcare providers scrambling to adhere to the documenting standards of MUR. The good news is, small-cap innovator MIT Holding, Inc. (OTC: MITD) has the solution providers need to comply.

As of January 2014, 20 different rules for doctors and 19 different rules for hospitals became mandatory under stage two of MUR. Medicare and Medicaid providers are now required to document a patient’s recovery after they are released from care. Gathering this information can be tricky. Some documentation, such as age, weight and gender, is easy to obtain. In-depth follow-up such as checking that the patient is properly taking their medication and following doctor’s orders for and rehabilitation, however, can be time intensive, hard to fill, and is at mercy of the patient’s truthfulness.

If the patient does not recover or the healthcare provider fails to properly document the recovery, the provider will be penalized in that Medicaid/Medicare will pay all of those same procedures billed for the next year at a lower payout. For example, if a hospital bills Medicare/Medicaid $10,000 for a procedure and the hospital does not provide the proper after-care documentation, the hospital is subject to penalty by Medicare/Medicaid. So if the penalty is 10%, the hospital would only receive $9,000 for that procedure over the course of the next 12 months.

This structure can have a dramatic impact on doctors and hospitals that lack the means, resources or the know-how to meet standard reporting. While healthcare providers can easily purchase the software and information technology (IT) needed to report the documentation, they still haven’t found a fully efficient way to gather the information. In fact, Frost & Sullivan reports that more than 50% of healthcare providers lack a plan of action to implement the health IT needed to improve care efficiency.

Managed Healthcare Executive recently published an article discussing the strategies and struggles of some of today’s leading care companies as they work to meet the new requirements. According to the article, Cigna Corp. (NYSE: CI), Aetna, Inc. (NYSE: AET), and Humana, Inc. (NYSE: HUM) utilize accountable care organizations (ACOs).

Cigna’s strategy, for example, is to execute patient outreach through the use of an “embedded care coordinator” with an ACO provider group. The company trains nurses, provides information on at-risk patients, and then informs nurses of which patients are being discharged from the hospital. The nurses then calls the patients at their home the day after their discharge to answer medical questions, confirm additional appointments, and keep patients educated on what to expect during recovery.

MIT Holdings’ solution offers doctors and hospitals the ability to refer their patients to the company’s comprehensive, one-source recovery service built on face-to-face patient contact. This first-of-its-kind service starts as soon as the patient is discharged from the hospital, at which time MIT assumes the responsibility of the recovery period. By building a personal relationship with the patient in the comfort of their own home, MIT has the unique ability to gather important information to meet MUR mandates.

If Cigna were to employ MIT’s solution, here’s how it would look: Cigna would be able to eliminate the expense and bureaucracy of the embedded care coordinator by eliminating the role altogether. Instead, MIT would meet with the patient at the time of discharge and if necessary would even accompany the patient home and help them determine each and every recovery need. MIT would also meet with other members in the household, and for the patient as well as those members would price pharmaceutical needs through the MIT pharmacy. Through this process, MIT, on behalf of Cigna, would establish a relationship with the patient that would promote clear and accurate communication, feedback and documentation. MIT is even capable of handling billing and insurance issues.

“We handle all the billing and all of the medical needs that an individual will need, and our record keeping will be through in-home interaction with the patient and will contain all of the information that Cigna, Aetna or Humana would need to report for the MUR,” explains William Nalley, IR representative for MIT Holding.

From the time of patient discharge from the medical facility, MIT’s services handle everything pertaining to the at-home recovery phase, including in-home medical equipment, infusion services, medications, follow-up appointments, organize therapy sessions, wound dressings, transportation, insurance inquires and professional insurance claim billing.

The goal is to make the patient feel like their care provider went home with them – there is no lapse in patient care or communication. All the patient needs to do is follow the MIT professional health caregiver’s instructions and recover while MIT documents the recovery of the patient, interacting with them one-on-one to help them properly, efficiently and quickly heal.

The digital paperwork MIT maintains in order to monitor the patients recovery contains all the information the hospital and doctors need to comply with the new rules. By recognizing the steep implications hospitals may face under the new requirements and developing a tested and sound solution, MIT has the potential to revolutionize the way doctors and hospitals gather and report patient recovery progress.

As more healthcare providers become aware of these services, MIT is catching wind in its sail, and recently reported first-quarter revenues of $489,854, more than double prior-year first-quarter revenues of $279,872. The company attributes this growth of 133.3% to an increase in customer referrals and subcontractor services. The first-quarter net loss of $9,654 represents a drastic cut from a loss of $105,726 a year ago. This resulted in a gross profit for the first quarter of $277,922, or 56.7%, as compared to gross profit for the same quarter in 2014 of $127,790, or 60.9%.

Moving forward, MIT will continue to market its comprehensive at-home recovery solutions and services as a viable solution to the healthcare industry’s growing demands.

For more information visit http://mitholdinginc.com/investors.html or contact William Nalley at 305-515-8077

[QualityStocks]

MITD Embraces The Affordable Care Act while Others Push Back, Achieves Better-than-Expected Q1 Results

MIT Holding saw its business grow above expectations in the first quarter, reporting triple-digit increases in revenues, service income and gross profit, and a drastically reduced net loss. The source for such incredible year-over-year growth? The company’s acceptance and adaptation to the Affordable Care Act (ACA).

While many companies have pushed back against the ACA, MIT Holding embraces the new healthcare law. Anything new means a change to the old ways of doing business. Fight the changes and you have a host of new problems to deal with on a daily basis. Change what you were doing, however, and those problems just seem to disappear.

Meaningful Use Rules under the ACA requires doctor and hospitals to document a patient’s recovery after discharge. This mandate creates significant obstacles for hospitals, such as how to track a patient’s recovery while they are at home and how to ensure they are taking the proper medications, therapies, and keeping multiple appointments. These challenges are sending hospitals nationwide scrambling to find a solution for these MUR requirements.

How serious is this to doctors and hospitals? Very. For example, let’s say a hospital bills Medicare/Medicaid for procedure “XYZ” and the allocated payment for that service is $10,000. The hospital must now follow up on the patient AFTER discharge.

Should the patient not recover or the hospital not properly document according to the rules, the hospital is penalized for the next year in that Medicaid/Medicare will pay all of those same procedures billed for the next year at a lower payout. So if the penalty is 10%, the hospital would only receive $9,000 for procedure “XYZ” for the NEXT 12 MONTHS.

Recognizing the steep implications hospitals may face under the new requirements under the ACA, MIT has developed a solution. MIT offers doctors and hospitals the ability to refer their patients to the company’s one-source recovery service. This first-of-its-kind concierge service starts as soon as the patient is discharged from the hospital, at which time they are met with an MIT representative. With the patient’s permission, MIT then assumes the responsibility of the recovery period.

MIT’s services are comprehensive to the at-home recovery phase, handling everything from in-home medical equipment, infusion services, medications, follow up appointments, therapy sessions, wound dressings, transportation, insurance inquires and professional insurance claim billing. The company’s goal is for the patient to feel as if the hospital went home with them. There will be no lapse in care. All the patient needs to do is follow the MIT professional health caregiver’s instructions and recover. On a daily basis, MIT will document the recovery of the patient, interacting with them one-on-one to help them heal properly, efficiently and quickly.

The digital paperwork the company maintains in order to monitor the patients recovery contains the information the hospital and doctors need to comply with the new rules. For a small and reasonable fee that information is now an email away.

With this solution, MIT has answered the question many hospitals are asking: “How do you track a patient once they have left the medical facility?”

When a pneumonia patient is discharged from the hospital and signed onto MIT’s system, the company expects that on average there will be from $12,000 to $15,000 in billable events. The company is prepared to capture those events and collect a fee for the digital paperwork documenting the recovery. A simple integration of the hospital software with MIT’s software should deliver that information in a format ready for filing with Medicare/ Medicaid.

The efficiency and growing popularity of MIT’s one-source solution is in the numbers.

In a recent 10Q filing, MIT reported first-quarter revenues of $489,854, more than double prior-year first-quarter revenues of $279,872. The company attributes this growth of 133.3% to an increase in customer referrals and subcontractor services. The first-quarter net loss of $9,654 represents a drastic cut from a loss of $105,726 a year ago. This resulted in a gross profit for the first quarter of $277,922, or 56.7%, as compared to gross profit for the same quarter in 2014 of $127,790, or 60.9%. Furthermore, new billing procedures improved the company’s accounts receivable by nearly 200%.

Moving forward, MIT will continue to embrace the ACA and the opportunities it provides for the company’s at-home recovery solutions and services.

“We deal in solutions not problems at MIT Holding and see no reason to fight the system,” says William Nalley, head of MIT’s investor relations. “When the problem occurs for the doctors and hospitals MIT Holding deliver the solutions. The benefit for MIT Holding is the captured billing events for that patient’s medical recovery.”

For more information, visit www.mitholdinginc.com

[QualityStocks]

MITD Initiates Awareness Campaign with Upcoming Investor Luncheons

New investor eyes. That’s what every publicly traded company needs. News releases, social media and articles are a great away to attract investor attention, but a company with substance still places a great value on face-to-face meetings with brokers, investment bankers and most importantly existing and potential shareholders.

Los Angeles-based MIT Holding is a provider of a professional one-source total recovery system that takes a patient from the hospital bed through full recovery. The company takes the responsibility of medications, appointments, the endless calls to the insurance carriers, home visits and, most importantly, the burden and stress of being sick and depending on family and loved ones.

MIT Holdings is gearing up for multiple investor luncheons scheduled for this summer. The luncheons will last approximately two hours and offer attendees one-on-one interaction to hear the full MIT Holding story and receive answers to any lingering questions.

“Even though just about every person alive can relate to our services and business model, because we are the first to create or pioneer this niche in the industry, it takes a little extra personal time to make sure the investor realizes what we have in fact created,” says William Nalley, IR consultant for MIT Holding. “We have reorganized the company and given our shareholders, for the first time, a self-sustaining business that needs no outside funding for day-to-day growth and an organic 25% year-over-year growth.”

Further explaining the business model, Nalley explains, “Think about it; anyone who has ever been through or has had a loved one go through a critical illness and attempt to navigate through the recovery period by themselves would give an arm and a leg to have one company to go to and say, ‘Here is my illness; this is what I need; take care of it!’ Well, we go one step further and meet with you in the hospital prior to discharge and start taking care of it at that moment. We go home from the hospital with you, so all you need to focus on is recovery.”

In support of its core services, MIT Holding also provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Your doctors, your medications and your hospitals will change throughout your life; MIT Holding will not. The company stays with its patients through the rest of their life, taking care of any medical needs that arise.

Combined, these services contribute to MIT Holding’s strategy to provide custom prescription solutions, maximize cross marketing, and generate multiple revenue streams.

MIT Holding has priced its services to achieve 32% minimum net profits and has maintained operational profitability in its fiscal third and fourth quarters, validating the company’s business model, its adaptable approach to the Affordable Health Care Act, and its potential in the health services industry.

Because MIT Holding meets and/or exceeds major U.S. health insurance requirements, the company can direct bill and receive payments from more than 128 carriers, Medicare and Medicaid on behalf of the patient its agents and its facilitators. This is an important component in the company’s goal of developing the first-of its-kind seamless transition for patient needs from hospital discharge to complete home recovery.

The ultimate desired outcome for meeting with brokers and shareholders is to raise brand awareness and transparency, and thereby potentially increase volume and liquidity.

“Once we increase those two factors, we become a different story. These luncheons are just another way to explain our business model and gain momentum,” explains Nalley. “Our intention is to do a year-long, nationwide investment/broker campaign. We’re going in and shaking the hands of brokers and making MIT Holdings management available for questions now and down the road.”

For more information, visit www.mitholdinginc.com

[QualityStocks]

MITD Reaps Strong Benefits from Corporate Reorganization Efforts

Since its establishment in 2006, MIT Holding has made major strides in expanding its healthcare service line. In addition to offering services to its patient base that includes home medical equipment, an ambulatory center and a compounding pharmacy, the company’s specialized educational programs have laid the foundation for more successful treatment throughout its operating region. Programs including healthcare professional training, clinician education programs, home infusion processes and emergency preparedness tips have allowed MITD to establish close relationships with healthcare providers and patients in the area, providing a significant foothold in a fragmented niche of the industry.

According to the company’s recent financial reports, its growth strategy is working. For full-year 2014, MITD achieved positive net income from operations of $14,152 compared to a loss of $1.12 million for the 12 months of 2013. MITD attributes the swing to its successful reorganization and renewed focus on its home health recovery business.

"Our in-home health recovery business, which facilitates and assists patients from the time of their release from a hospital through a full in-home recovery, is now in place," Tommy Duncan, president of MITD, stated in the news release. "This was an area of significant focus in our restructuring efforts and which led to our financial turnaround in 2014. We look for continued growth in this business in 2015 and beyond."

To satisfy the need for additional revenue streams moving forward, MITD has focused on the assembly of a strong portfolio of licenses, contracts, agreements and working arrangements designed to create a ‘one-stop-provider’ of services for patients in transition between inpatient and outpatient care. With the health care system continuing to push for quicker patient discharges, the company is strategically positioned to fill the gap in an environment that now places much of the responsibility throughout the recovery process on the shoulders of patients.

“Our goal is to ease this burden and create for patients a single source for all of their necessary medical products and services. We want to care for the patient for the rest of their lives, for any future medical needs” said Duncan.

As the company continues to make strides towards establishing itself as a leader in medical and technological innovations designed to enhance the quality of life of patients, look for continued growth in the rapidly changing medical industry.

According to a report from Health Affairs, unsustainable costs is forcing the U.S. healthcare system to transform into a more outpatient, community-based model. With this trend in mind, MITD is in a strong position to grow its influence for years to come.

For more information on MIT Holding, visit www.mitholdinginc.com

[QualityStocks]

MITD Achieves $1 Million Turnaround and Positive Net Income from Operations

Today before the opening bell, MIT Holding proudly reported that it has achieved positive net income from operations in 2014.

Last week the company filed a Form 10-K with the SEC showing a net income from operations of $14,152 in 2014 compared to a net loss from operations of ($1,123,830) for the same period a year earlier. The company attributed this dramatic change to the company’s overall restructuring efforts and renewed focus on its in-home health recovery business.

“Our in-home health recovery business, which facilitates and assists patients from the time of their release from a hospital through to a full in-home recovery, is now in place,” commented Mr. Tommy Duncan, President of MIT Holding. “This was an area of significant focus in our restructuring efforts and which led to our financial turnaround in 2014. We look for continued growth in this business in 2015.”

Demand for low cost, high quality home care will only increase as payers realize up to 90% saving on infusion services performed in the home versus in the hospital. According to Harris Williams & Co, the United States home infusion market is $15.9 billion and is expected to reach $26.7 billion by 2020, resulting in a compound annual growth rate of 9.02% per year.

Mr. Duncan further commented, “Our target audience is focused on those needing infusion for recovery. Many infusion therapies cost more than $10,000 per patient, per year. Patients receiving treatment usually require special counseling and education regarding their condition and treatment. Retail pharmacies and other traditional distributors generally are designed to carry inventories of low cost, high volume products. Our platform is based on the delivery of these high cost, low volume specialty pharmaceuticals that have specialized handling and administration requirements.”

For more information, visit www.mitholdinginc.com

[QualityStocks]

MITD Innovative Healthcare Model Boasts Tri-Fold Effect

MIT Holding has carefully established a network of agents, facilitators and contractual obligations through which it believes is the opportunity to greatly enhance the healthcare industry. The Los Angeles-based company is a single-source provider for medical recovery services, specifically for the fourth and fifth phases of medical recovery: the dependent patient and recovery/rehabilitation stages.

Here’s how it works. An MIT representative meets with the hospital discharge planner and patient on the day of the patient’s discharge from the medical facility. This representative takes full responsibility in arranging in home or local clinic appointments, medication, medical equipment needs and insurance approvals for the patient, enabling them to focus on the recovery at hand without additional stress. In most cases, the products and services offered by MIT are already pre-approved by the patient’s health insurance, which enables the company to directly bill and receive payments from carriers on behalf of the patient as well as company agents and facilitators.

The company’s current line of services includes professional outpatient medical care such patient pharmaceuticals, intravenous infusions, medical management services, and in-home or ambulatory center therapies. In addition, durable medical equipment services (DME) enable the company to offer for sale or rent, home medical equipment, from crutches to hospital beds.

MIT also offers legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; and travel and transportation services of medically challenged patients for medical needs and personal travel.

Need for these services arise from pressure for doctors and hospitals to lower costs, which results in patients being released from the hospital earlier to reduce the cost of care.

By offering a complete need-fulfillment for the patient during their at home recovery period, MIT’s services assists the patient through recovery, helps healthcare facilities lower their costs, and creates opportunities to cross market its goods and services to enhance revenues streams.

Following a successful reorganization initiative launched at the start of last year, MIT is now positioned to achieve 32% minimum net profits and maintain profitability. This profitability validates the company’s business model and its approach to the evolving health services industry.

According to the latest figures from the Centers for Disease Control (CDC), in 2013 more than 35 million patients were discharged after a nearly five-day stay in a non-federal hospital. The same year, outpatient services exceeded 100 million patients in non-federal facilities. Based on these figures, MIT is tackling a market opportunity of more than 135 million patients to which it can cross market its invaluable products and services while working toward its broader mission to lead medical and technological innovations to enhance the physical, emotional and aesthetic quality of life.

For more information, visit www.mitholdinginc.com

[QualityStocks]

MITD Well-Positioned to Continue Racking Up Profitable Quarters as Healthcare Industry Transitions from Inpatient to Outpatient Care

There has been a gradual but consistent shift in healthcare over the last decade or so from inpatient stays to ambulatory care (outpatient care) and the advent of the Patient Protection, as well as the Affordable Care Act (ACA), have accelerated this transition in the overall healthcare business model substantially. According to healthcare advisory firm Kaufman Hall, inpatient utilizations (per 1k) continually declined from 2000 to 2011 and 71% of the states in their study showed decreases of over 5%. A clear trend which is further evinced by Fitch Ratings’ report from August of 2014 showing a marked decline in inpatient activity and a corresponding rise in ambulatory care in their sweeping rated hospital and health system portfolio.

Some of the core reasons behind this transition are a growing focus on risk-sharing arrangements and coordinated or collaborative care, as well as the increasingly prominent financial benefits of value-based payment models, particularly under the ACA, which has optimized the playing field for low-cost, high-quality service in the most convenient settings for the patient. With Medicare providing coverage to some 54 million seniors last year, totaling $615.9 billion (including beneficiary premiums) and the number of those covered set to rise sharply within the next 15 years to around 81.4 million, as Baby Boomers continue to retire in droves, a perfect storm is brewing in the outpatient care services market. Total expenditures on healthcare in the U.S. for 2014 ran around $3.09 trillion, or 18% of GDP and these costs are projected to rise 15.5% by 2017 to over $3.57 trillion, making the future for service and product providers, particularly those who can master the rising trend towards ambulatory care, a very bright one indeed.

One of the larger hospital and home care agency focused providers in the U.S., Community Health Systems (NYSE:CYH), serves as an excellent benchmark for the ongoing transition to ambulatory care, with total associated revenues up around 1% year over year to 55.8% in 2014. Other large hospital operators, like HCA Holdings (NYSE:HCA) and Tenet Healthcare (NYSE:THC), also saw large chunks of their bottom line attributable to ambulatory care last year, at around 38.4% and 36.2% of revenues respectively. South Nassau Communities Hospital (Oceanside, NY) is another good benchmark here, with a 62% to 38% inpatient to outpatient mix only five years ago, having shifted to a 59% to 41% mix as of last year. COO and Executive VP of Administration for the hospital indicated that their experiences were consistent with the broader industry trend and that the drive to improve outcomes and service in a cost-effective manner was a major priority as South Nassau Communities Hospital as they transitioned more and more of their overall care footprint from the hospital to the community.

One of the exciting up and comers to provide an innovative approach amid this growing trend is MIT Holding (OTCQB:MITD), which has developed a portfolio of products and services ranging from custom compound pharmaceuticals and a wide variety of sold/rented home medical equipment, to IV infusions, ambulatory/in-home therapies, and medical management services. The company has emerged after a profile build up and reorganization to post back-to-back profitable quarters (as of Q2 2014) on the strength of several significant new revenue streams, including two key contracts with the first company to automate the patient transition process, Curaspan Health Group, whereby MITD can market their products and services directly to patients of Curaspan’s 5.4k plus medical facilities.

As of the start of last year, MITD revenues were on-track for a 32% net profit baseline and the company is pricing future business on that basis. One of the new revenue streams, a sub-investigator role (via the company’s facilitators) initiated back in November of 2014 for the main investigator in a Phase 3 study evaluating treatments for complicated bacterial and soft tissue infections, Melinta Therapeutics, not only validated the company’s approach to landing more business in this lucrative and highly specialized market, it opened the door for expansion of the contract on this 12-month study featuring two to four hour patient infusions and came with a 52% gross profit margin. Growth opportunities like the sub-investigator role in the Melinta study matches the company’s business model. MITD’s approval by over 130 insurance carriers goes a long ways towards helping to cement the company’s role as a chief sub-investigator. The Melinta study highlights a now established and growing presence in this highly profitable space for MITD.

Take a closer look at the company by visiting www.mitholdinginc.com

[QualityStocks]

MITD Pioneers Single-Source Approach to Revolutionize Outpatient Medical Home Medical Care

Los Angeles-based MIT Holding, operating through its network of accredited agents, facilitators and contractual obligations, has developed a single-source approach geared to simplify professional outpatient medical care for the roughly 135 million people discharged from inpatient hospital care in the U.S. each year.

The company provides a comprehensive set of outpatient services designed to accelerate patient recovery by providing them with ultimate convenience and by reducing stress associated with coordinating and receiving appropriate products and care. MIT’s services are provided within the comfort of the patient’s home and include ambulatory infusion therapies, home infusion services and medical equipment delivery.

Additionally, because MIT is in compliance with major U.S. health insurance requirements, the company is able to direct bill and receive payments from carriers on behalf of patients, agents and facilitators. The result is a seamless transition for patient needs from hospital discharge to complete home recovery.

MIT has completed beta tests on its single-source concept, successfully providing medical recovery services from the point of discharge from the hospital or medical facility to full recovery. The company’s initiative is to use the testing as a catalyst to grow its presence nationwide and expand through one strategic acquisition per quarter.

In support of its core services, MIT also provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act.

Demonstrative of the company’s flexibility and progressive insight to the healthcare industry, MIT also offers travel and transportation services of medically challenged patients for medical needs and personal travel. Furthermore, through its contracts, MIT is approved to conduct and administer FDA clinical trials.

Together, these services are the foundation of MIT’s mission to provide custom prescription solutions in a variety of methods while generating multiple revenue streams and increasing shareholder value.

Thanks to a strategic and successful reorganization initiative in 2014, MIT is positioned to achieve 32% minimum net profits and has maintained profitability in its fiscal second and third quarters. This profitability underscores the company’s unique concept and its relevance to the health services industry.

For more information, visit www.mitholdinginc.com

[QualityStocks]

MITD's Home Health Services Model is Complementary to Broader Medicare Goals

Nearly 14% of Medicare patients discharged to a skilled nursing facility (SNF) after a hospital stay are readmitted to the hospital for conditions that could have been avoided with better care, according to MedPAC analysis. A collaborative effort between the Partnership for Patients and the Center for Medicare and Medicaid Services (CMS) aims to reduce hospital readmissions by 20% and save the healthcare system tens of billions of dollars in upcoming years. MIT Holding has a complementary approach: a single source of high-quality, low cost need-fulfillment for patients provided during their at-home recovery.

Research shows that sufficient homecare recovery after a hospital stay can drastically reduce mental and physical stresses on the patient, minimize the length of recovery and associated costs, and reduce the risk of hospital re-admission and hospital acquired conditions.

MIT Holding has built its business model around this concept, and works through its growing network of accredited agents, facilitators and contractual obligations to operate as a single-source provider of professional outpatient medical care including pharmaceuticals, intravenous infusions, medical management services, and in-home or ambulatory center therapies, in addition to home medical equipment for sale or for rent.

The company also provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Furthermore, as an accredited healthcare provider, MIT is in full compliance with major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators.

In June, 2014, MIT achieved its first profitable quarter in six years, and each company subsidiary is now operating with objectives of a 32% net profit. This profitability validates MIT’s approach to the evolving Affordable Health Care Act as well as the company’s impact on patient recovery and the broader healthcare industry.

MIT recently completed successful beta testing of its concept in Georgia and now plans to expand its first-of-its-kind approach nationwide via one acquisition per each quarter of 2015. The company’s broader business model is focused on building shareholder value, revenues and corporate expansion while providing viable solutions to the changing care sector.

For more information, visit www.mitholdinginc.com

[QualityStocks]

Home Recovery Health Services Model by MIT Holding, Inc. (MITD) Features Cross-Marketing Advantages

The road to recovery can, but doesn’t have to, be a long, stressful and expensive one. Adequate homecare after a hospital stay can play a substantial role in reducing the mental and physical stresses on the patient, thereby minimizing the length of recovery, associated costs and reducing the risk of hospital re-admission.

Los Angeles-based MIT Holding has developed a unique approach to the fourth and fifth phases of medical recovery – the dependent patient and recovery/rehabilitation stages – by offering a complete need-fulfillment for the patient during their at-home recovery period following a medical event.

MITD’s single-source approach provides a personalized recovery period in which more patient information and recovery needs are discovered and efficiently addressed for the patient. Through its current portfolio of services, MITD can arrange for patient pharmaceuticals, intravenous infusions, medical management services, and in-home or ambulatory center therapies. In addition, durable medical equipment services (DME) enable the company to offer home medical equipment, from crutches to hospital beds, either for sale or for rent.

By shouldering these components of the recovery process, this innovative concept greatly benefits the care provider and patient while allowing MITD to cross market its goods and services to the patient to enhance revenue streams.

The actual model is designed as such: an MITD representative meets with the hospital discharge planner and patient on the day of the patient’s discharge from the medical facility. The MITD representative alleviates patient burden by taking full responsibility in arranging in home or local clinic appointments, medication, medical equipment needs and insurance approvals. In most cases, the products and services offered by MITD are already pre-approved by the patient’s health insurance. MITD meets and/or exceeds major U.S. health insurance requirements, which enables the company to directly bill and receive payments from carriers on behalf of the patient as well as company agents and facilitators.

Until MIT Holding stepped into this space, there was virtually no single-source service provider of an all-inclusive product line of medical goods and services for this mandatory market.

As an example of how the model works, consider the fact that a patient recovering from a respiratory illness will typically require four-to-six weeks of recovery. In this case, ta patient’s visit usually requires a four-hour visit from a registered nurse (RN) to administer an intravenous infusion of antibiotics. During the visit the RN will review the patient’s prescription history and current medications. Any additional medications the patient or other family members are taking will be priced through MITD’s affiliated compound pharmacy and delivered directly to the home.

Insurance companies will normally pay for most items and services that will speed recovery. For example, patients with a respiratory illness are advised to sleep in a reclined position. The insurance company will not buy a hospital bed, but they are likely to cover the cost of a temporary rental.

When you consider the number of patients in need of at-home recovery assistance, it’s obvious why MITD is innovating in this market of the healthcare industry.

According to a CDC Report, in 2013 alone more than 35 million patients were discharged after a nearly five-day stay in a non-federal hospital. In the same year, outpatient services exceeded 100 million patients in non-federal facilities. These facilities normally have an insured or self-insured patient base.

Based on these figures, MIT Holding sees a nationwide market potential of more than 135 million patients annually to which it can cross market its invaluable products and services while working toward its broader mission to lead medical and technological innovations to enhance the physical, emotional and aesthetic quality of life.

For more information, visit www.mitholdinginc.com

[QualityStocks]

MITD Offers Patients an Opportunity to Relax in Style

With advancements in medicine, technology and quality of life, people are, on average, living much longer these days than they ever have before. In an effort to further improve quality of life for its patients, MIT Holding, Inc. (OTCQB: MITD) partners with hospitals, physicians, facility based providers, pharmaceutical manufacturers and healthcare payers, through its portfolio of services, to provide post-acute care to patients nationwide. In addition to educational programs and in-home treatment options, the company offers unique travel ventures designed to dramatically improve its patients’ quality of life without creating unnecessary medical risk.

The MIT Holding’s Medical Sea Cruises program will offer individuals who require dialysis or infusion treatment the opportunity to travel abroad with family and friends without missing out on required medical care. The company’s commitment to the care of its patients is the foundation for its unique travel options. With dedicated and trained medical professionals readily available throughout their vacation, patients can relax in style without unnecessary fear of health-related complications.

The company’s travel programs open the door for thousands of patients whose travel may have been highly restricted in the past. According to reports from the Centers for Disease Control and Prevention, an estimated 29.1 million people, or 9.3% of the U.S. population, struggle with diabetes, which accounts for just over 38% of kidney failure cases throughout the country. As a result, nearly 230,000 people of all ages live on chronic dialysis, which can seriously restrict the opportunity for prolonged travel.

The company’s mission is to be the leader in medical and technological innovations created to enhance the physical, emotional and aesthetic quality of life of its patients. While MIT Holding continues to serve its patients throughout Georgia and South Carolina with high quality ambulatory care and home infusion services, few programs can compare to the potential to enhance the overall freedom and quality of life of patients presented by the company’s Medical Sea Cruises program.

For more information on MIT Holding, visit www.mitholdinginc.com

[QualityStocks]

MITD's In-Home Medical Recovery Services Hold Potential for Future of Healthcare

Many successful innovations fulfill an unmet need, whether realized or not. Creation of these innovations stems from progressive thinking, a visionary mindset, and the powerful capability to properly plan and execute a strategy for the desired outcome. The healthcare industry’s bumpy road to change is pocked with numerous unmet needs, and MIT Holding is traveling this course to provide an innovative first-of-its-kind solution to pave over many of these needs.

MIT Holding is a single-source provider for in-home medical recovery services. Specifically, the company, through its portfolio of service agreements, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas. Need for these services arise from pressure for doctors and hospitals to lower costs, which results in patients being released from the hospital earlier to reduce the cost of care.

Focused on how present issues and solutions will greatly impact the future of healthcare, MIT Holding’s innovative platform has potential to be an integral component of industry change. The company’s concierge services meet the patient when they are discharged from the hospital and help them transition through complete recovery – in essence picking up where the hospital left off.

Backed by a visionary and aggressive management team, MIT Holding is in a prime position to duplicate its business model to the benefit of the company itself, hospitals seeking cost reduction, and patients in need of an assisted, stress-free in-home recovery. The company sees multiple cross marketing opportunities for its professional recovery services model to be implemented into the core of the healthcare recovery industry.

Following a successful beta testing of the model in Georgia, MIT Holding management is pioneering this new concierge concept to travel nationwide via strategic acquisitions. Aiming to achieve one acquisition per quarter, MIT Holding is seeking out accredited and profitable acquisition targets that will add value to the broader business model.

For more information, visit www.mitholdinginc.com

[QualityStocks]

MITD Introduces First-of-its-Kind In-Home Concierge Medical Service

Imagine you’re in the hospital, preparing to check-out the following day. Knowing the recovery ahead will require certain accommodations, you phone downstairs to the concierge desk and say, “I’m checking out tomorrow; would you please make all the arrangements for my recovery at home?”

If that doesn’t sound like the steps taken by you or a loved one following release from a hospital in the past, it’s because the service didn’t exist. Until now.

With MIT Holding’s patient-centered approach, you can call and request comprehensive in-home concierge services designed to accelerate and ease your recovery. There are many stages in the illness process, and MIT Holding is emerging as a single source provider of medical services for patients making the vital transition from stage three to stages four and five.

In 1965, research scientist Edward Suchman defined the stages of illness and the transition between them as:

1) The symptom experience stage
2) The sick role stage
3) The medical care stage
4) The dependent patient stage
5) The recovery or rehabilitation stage

Management at MIT Holding studied the five stages in today’s healthcare system and found that the two most crucial yet most ignored stages were four and five. Due to the fact that the fourth and fifth stages are often completed in the patient’s home, these final stages are the least studied. Other than the typical “see me in two weeks” checkup and physical therapy (if needed), there is limited professional medical involvement in the patient’s transition through recovery and rehabilitation.

The lack of services in the final stages – which MIT Holding deems the most stressful, because recovery is now on the patient’s shoulders – representing a dire need within the healthcare industry. Patients often feel a loss of control and sense of guilt as they become dependent on family members and friends for assistance. Some situations even introduce humiliation to the equation when a patient is bed ridden and in need of basic sanitary assistance.

When a loved one tells the patient they look great, the patient may shrug it off as empty words of kindness. When the professional tells them the same thing it tends to have a positive meaning and begins to incubate recovery on a mental level for the patient, as well as physical. Similarly, loved ones urging the patient to take their medication or rehabilitation is often dismissed by a patient. The same instructions coming from a healthcare professional are heeded as “doctor’s orders” and followed.

Following years of surveys and interviews with past and current patients, MIT Holding developed its concept of single source medical services to address these stages required for recovery and rehabilitation. By introducing MIT Holding’s medical professionals into the equation, the company aims to instill within each patient a renewed sense of dignity, responsibility, and focused level of control over their recovery. With the emotions and stress reduced, the result is quicker recovery and confidence building steps toward regained independence.

Through its research, MIT Holding also realized that by working directly with hospital discharge planners prior to release, the patient would experience a seamless transition from hospital to home. MIT Holding eliminates discharge hassles such as dealing with the bureaucratic hassles of the insurance companies, pharmacy, medical equipment suppliers and specialized transportation needs. MIT professionals have been trained and accredited to quickly and efficiently execute these arrangements on behalf of the patient.

The Centers for Disease Control (CDC) reports that the number of first-time pneumonia cases in the U.S. exceeds 35 million annually. The typical hospital stay is roughly five days followed by home recovery of four to six weeks depending on the severity of the case. Astoundingly, the recovery period alone can cost approximately $12,000 to $14,000, with no complications.

MIT Holding’s services drastically reduce these costs. Using a patient with pneumonia as an example, here is how the company’s solution works.

On the day of discharge from the hospital, the patient is met by an MIT Holding staff member, introduced to the company’s streamlined recovery process, and informed of the medical needs for their recovery period. The staff member will also explain to the patient all the options covered by their insurance and what will be the patient’s responsibility..

Pneumonia requires an antibiotic infusion often weekly for a four- to six-week period. Using MIT Holding’s services, the patient has the option of in-home care or access to one of MIT Holding’s local clinics to receive the treatment, which require a two- to four-hour administration session. Whether in the patient’s home or in the clinic, MIT Holding’s professional staff interacts with the patient to determine their individual needs throughout the treatment.

The staff also lobbies on the patient’s behalf for ancillary recovery needs. For example, patients recovering from pneumonia are advised to sleep in a reclined position. MIT Holding can verify if the insurance carrier will pay for a temporary rental of a hospital bed or medical recliner through recovery – and then make arrangements for its delivery and pick up. Should the patient live alone, MIT Holding can arrange for additional daily help as needed to maintain a sanitary recovery environment. In addition, the company’s compound pharmacy will deliver the antibiotics and other oral medication directly to the patient.

The extended time and personal care spent with the patient ensures that each patient receives every benefit to which they are entitled or choose to purchase for the most comfortable recovery possible. MIT Holding works with each patient to ease the burdens of recovery. Simply put MIT Holding deals in solutions – not problems!

MIT Holding has learned and proven that by extending superior care to the patient on multiple fronts, the company itself will benefit through multiple, growing revenue streams. Beta tests of this approach have shown an average increase in sales of up to 27% on a typical patient interaction – and the company is just getting started implementing its innovation into the U.S. healthcare system. Its potential has yet to be seen or achieved.

MIT Holding is pioneering the future of healthcare, positioned as the first-of-its-kind single source provider of medical services stemming from a convenient, all-inclusive concierge concept with no additional cost to the patient.

For more information, visit www.mitholdingsinc.com

[Pennybuster]

$MITD Up Over 70% Today.. On Radar Here..

[Pennybuster]

$MITD wo Steps Ahead of Industry Evolution, MIT Holding, Inc. (MITD) Pioneers Modern Healthcare

On MIT Holding’s website, you’ll find the tagline “Leading the way for today and the next generation.” Catchy, but what exactly does that mean? MIT Holding is a single-source provider for in-home medical recovery services. Sounds simple enough, but it’s an innovative business model based on a quiet evolution within the healthcare industry and the company’s foresight to prepare for and capitalize on impending industry changes.

MIT Holdings partners with hospitals, physicians, facility-based providers, pharmaceutical manufacturers and other contractual affiliates to provide patients with sweeping out-patient services. The company meets and/or exceeds major U.S. health insurance requirements, which enables them to directly bill and receive payments from carriers on behalf of the patient as well as company agents and facilitators.

Here’s how the actual recovery services platform works. Upon his or her release from the hospital, a patient meets with a discharge planner who is responsible for helping the patient transition to the next level of care. Depending on the procedures performed, this transition can take weeks, months or years, and in some cases for the remainder of the patient’s life.

When in-home rehabilitation is recommended, the planner would refer the patient to MIT Holding. Through its portfolio of services, MIT Holding then provides its comprehensive medical products through a concierge type service at no additional cost to the patient.

The patient may need a range of services from ambulatory, infusion, durable medical equipment (DME), pharmacy services, improved sanitary spaces, transportation and other recovery services or products. MIT Holding can arrange any or all of these services for the patient. This contractual model creates numerous revenue streams for MIT Holdings along with tremendous cost savings for the patient and insurance company.

“The goal is to provide a non-stressful healing environment possible. The belief is recovery will happen much faster because we meet patients in their home environment, not in a stressful sterile medical facility. The patient completes recovery quicker, insurance company pays less over time creating a win-win situation,” says William Nalley, president of the Orsay Group, Inc., and IR advisor for MIT Holding.

The Affordable Care Act creates pressure for hospitals and doctors to lower costs, and as a result, more people are being discharged earlier from hospitals to reduce the cost of patient care. The cost-saving aspects of MIT Holding’s innovative platform are part of the reason the company believes its business model will be a solid and widespread component of the healthcare industry.

“The Affordable Care Act is a positive for us … one thing it is requiring of hospitals, doctors and medical care in general, is lower prices for services. For the patient, that typically equates to a quicker exit from the hospital or medical facility. We’re the company ¬with our arms open wide saying ‘come to us, we’ll pick up where they left off.’ Imagine if on the last day of your hospital stay you phoned downstairs to the concierge desk and asked: ‘Can you please arrange everything for my home recovery please?’ MIT representatives will come to your room and meet with you to make those arrangements,” Nalley explains.

MIT Holding’s model is an active model. Through its current portfolio of services, the company can arrange for patient pharmaceuticals, intravenous infusions, medical management services, in-home or ambulatory center therapies. The durable medical equipment services (DME) enable the company to offer for sale or rent, home medical equipment, from crutches to hospital beds.

MIT Holding has beta tested its single-source provider concept in Georgia, and to management’s knowledge, is the first to provide this type of comprehensive service within the home medical services industry. The company’s goal is to use its industry-pioneering business model to maintain a number one position in this new industry concept and expand with a nationwide footprint via strategic acquisitions. To achieve this goal a one acquisition per each quarter is the 2015 corporate goal.

“We have the platform for these services in place and we’re ready to duplicate state-by-state,” says MIT Holding chairman and CEO Walter Drakeford. “It’s a tall order to fill, but the company has a clearly defined plan to achieve this mission. The business model is more than gobbling up the first acquisition target to come along. At the core of this precision-based strategy is facility accreditation.”

Accreditation ensures that a facility adheres to certain procedures and guidelines set by each state to insure services and billing are correctly rendered. It’s basically a way to make sure people aren’t opening up companies in the garage of their homes and billing services for deceased patients.

The accreditation process is extremely thorough, taking into consideration various information in 12 different divisions and covering everything from operations to billing, finances and small day-to-day activities. It’s this meticulousness that deters many medical facilities from ever becoming accredited. While it’s not mandatory that facilities become accredited, every supplier of medical equipment has to be accredited to be able to contract with Medicare. Additionally, accreditations must be renewed every two years.

This accreditation is an integral part for MIT Holding’s relationship with its more than 130 insurance provider partners. One of MIT Holding’s affiliates started its accreditation process January 1 to prepare for the June 6, 2015, expiration.

“Preparing for [the accreditation] on the company’s end is something that is time consuming and difficult, but it’s making sure that we have everything in place; which we do,” stated a representative assisting in MIT Holding affiliates accreditation renewal process. “It’s important that the accreditation is passed and every employee is up to par in terms of what the company stands for and what the company requires us to do.”

In fact, if the affiliate had chosen not to renew its accreditation, MIT Holding would have scrapped the partnership; here’s why. The Affordable Care Act does not affect the accreditation process. As such, the accreditation itself has helped legitimately operating companies while unraveling the operations of those that were not.

For example, at one time, the cost of care for patients on oxygen was never capped-out. The insurance company could be billed for the oxygen for as long as the patient lived, whether or not the supplying company ever had contact with the patient. Under the Affordable Care Act, oxygen gets capped out at 36 months. At this point, the supplier has to maintain contact with that patient to make sure they indeed are alive and in need of oxygen. In essence, the Affordable Care Act came in and cleaned house.

“An accreditation sticker on your door shows that you are a reputable company – that you do things beyond the norm in terms of standards. You have had a third party come in and review everything and they have stamped you with a seal of excellence. The accreditation process now has become something that everyone strives to have, not only for insurance reasons but also to show to the community the physicians and the patients that you are a legitimate company upholding the highest patient standards,” says Drakeford.

Here’s where it ties back to MIT Holding. As earlier noted, MIT Holding’s aggressive expansion strategy calls for an acquisition per quarter – however, acquisition or affiliate targets lacking accreditation or not in the process of doing so won’t get a second look from MIT Holding. And it’s been that way for years, according to Drakeford.

“MIT had the foresight two years ago to look at the Affordable Care Act and see the benefits and how to achieve the best results for the company, our patients and our shareholders by adhering to accreditation standards and exemplifying those requirements for anybody we bring on board to duplicate our platform in other states,” he says. “As MIT continues to grow, the affiliations and affiliates that we work with must be accredited. If you’re not professionally respected in your category, you’re not an MIT candidate.”

The company expects that in the next 5 to 10 years it will be mandatory that everyone will be accredited. If true, the requirement would squeeze the number of people that are entering the industry because the standards and expense will be too high. On that note, MIT Holding will be ahead of the game.

“Whether it be on the DME side, the pharmacy side, ambulatory side or infusion side we are seeing certain criteria starting to slowly come into play that in the next 10 years will be factored into whether a company will succeed or fail,” says Drakeford.

MIT Holding plans to duplicate its platform across the U.S. by assembling a portfolio of key affiliates and acquisitions that not only meet accreditation standards, but MIT Holding standards as well.

Among several other criteria, MIT Holding is looking for profitable acquisition targets with a spotless billing history and strong management with an established set of internal controls in place. Accreditation is also a requirement, though companies in the process of accreditation or positioned to initiate the process will be considered. MIT Holding has a few acquisition targets that fit the bill and that are currently undergoing due diligence.

In June, 2014, MIT Holding achieved its first profitable quarter in six years thanks to corporate re-organization initiated in fiscal year 2011. Each MIT Holding subsidiary is now operating with objectives of a 32% net profit. The MIT concept can still deliver services and goods for less than the local medical facility.

Leveraging this improved position, MIT Holding has developed a platform years ahead of its time. As hospitals discharge patients earlier to lower hospital costs, and as accreditation moves toward potential mandate status rather than an option, the company’s strict accreditation policy adds power to its charge at the head of the pack. With patient care in order, MIT Holding is now focusing on shareholder value.

“The accreditation is an example of the height of the demands MIT Holding has on anybody affiliated with the company, which ultimately will reflect through to revenues, shareholder and company valuation,” says Nalley. “We’re now in a position that we can duplicate what’s occurred in Georgia in any other state in the country. MIT makes an acquisition of a facility within that target state, bringing them under our umbrella – and we’re now marketing in that state. Growth of MIT Holding will be the ultimate reward to the shareholder.”

For more information, visit http://www.mitholdingsinc.com

[Pennybuster]

$MITD DD Notes ~ http://www.ddnotesmaker.com/MITD

ddnotesmaker.com
remove forum tags
$MITD recent news/filings

## source: finance.yahoo.com

Mon, 02 Feb 2015 13:58:00 GMT ~ MIT Holding (MITD) Launches New Website with Investor Relations Suite

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 2, 2015 / MIT Holding, Inc. (MITD.OTCQB)(the "Company") announces the launch of its new, redeveloped website ( http://mitholdinginc.com ), which features ...

read full: http://finance.yahoo.com/news/mit-holding-mitd-launches-website-135800946.html
*********************************************************

Tue, 20 Jan 2015 13:30:00 GMT ~ MIT Holding, Inc. Names Tommy J. Duncan as President

[Marketwired] - MIT Holding, Inc. today announces Tommy J. Duncan as president of day-to-day operations at MIT Holding. This appointment coincides with the initiation of the Company's second phase of corporate re-organization....

read full: http://finance.yahoo.com/news/mit-holding-inc-names-tommy-133000081.html
*********************************************************

Fri, 09 Jan 2015 14:10:54 GMT ~ MIT Holding, Inc. (MITD) Announces Engagement of QualityStocks Investor Relations Services

[Marketwired] - MIT Holding, Inc. today announces that it has engaged the investor relations services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their ...

read full: http://finance.yahoo.com/news/mit-holding-inc-mitd-announces-141054960.html
*********************************************************

Thu, 27 Nov 2014 18:04:22 GMT ~ MIT HOLDING, INC. Financials


read full: http://finance.yahoo.com/q/is?s=mitd
*********************************************************

Thu, 20 Nov 2014 14:45:00 GMT ~ MIT Holding, Inc. (MITD) Announces Profitable 3rd Quarter Financial Results

[Accesswire] - Company Posts Second Straight Quarterly Profit Los Angeles CA / ACCESSWIRE / November 20, 2014 / MIT Holding, Inc. (OTCQB: MITD) a health care services company today announced its 3rd quarter 2014 financial ...

read full: http://finance.yahoo.com/news/mit-holding-inc-mitd-announces-144500760.html
*********************************************************


$MITD charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$MITD company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/MITD/company-info
Ticker: $MITD
OTC Market Place: OTCQB
CIK code: 0001367416
Company name: MIT Holding, Inc.
Company website: http://www.mitholdingsinc.com
Incorporated In: DE, USA

Business Description: Convention All Holdings, Inc. is a Delaware corporation formed on June 22, 2006, to acquire all of the shares of Convention All Services, Inc., an Illinois corporation formed on January 2, 1986. As a result of the closing of a share exchange agreement with the shareholders of Convention All Services, Inc, on August 7, 2006, Convention All Services, Inc., an Illinois corporation, is now the wholly-owned subsidiary of Convention All Holdings, Inc.


$MITD share structure

## source: otcmarkets.com

Market Value: $5,131,835 a/o Feb 03, 2015
Shares Outstanding: 88,479,914 a/o Nov 05, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$MITD extra dd links

Company name: MIT Holding, Inc.
Company website: http://www.mitholdingsinc.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MITD/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MITD/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MITD+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MITD+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MITD+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MITD/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MITD/news - http://finance.yahoo.com/q/h?s=MITD+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MITD/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MITD/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MITD/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MITD/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MITD/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MITD/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MITD/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MITD/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MITD+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MITD
DTCC (dtcc.com): http://search2.dtcc.com/?q=MIT+Holding%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=MIT+Holding%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=MIT+Holding%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.mitholdingsinc.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.mitholdingsinc.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.mitholdingsinc.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MITD/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MITD
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MITD/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MITD/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MITD/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367416&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MITD/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MITD/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MITD/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MITD/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MITD&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MITD
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MITD/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MITD+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MITD+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MITD
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MITD
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MITD+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MITD/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MITD+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MITD.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MITD
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MITD/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MITD/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MITD/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MITD/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MITD
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MITD
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MITD:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MITD
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MITD


$MITD DD Notes ~ http://www.ddnotesmaker.com/MITD

[QualityStocks]

14-page Investor Relations Kit is Now Available Online
http://mitd.qualitystocks.net/ir/

[QualityStocks]

Two Steps Ahead of Industry Evolution, MITD Pioneers Modern Healthcare

On MIT Holding’s website, you’ll find the tagline “Leading the way for today and the next generation.” Catchy, but what exactly does that mean? MIT Holding is a single-source provider for in-home medical recovery services. Sounds simple enough, but it’s an innovative business model based on a quiet evolution within the healthcare industry and the company’s foresight to prepare for and capitalize on impending industry changes.

MIT Holdings partners with hospitals, physicians, facility-based providers, pharmaceutical manufacturers and other contractual affiliates to provide patients with sweeping out-patient services. The company meets and/or exceeds major U.S. health insurance requirements, which enables them to directly bill and receive payments from carriers on behalf of the patient as well as company agents and facilitators.

Here’s how the actual recovery services platform works. Upon his or her release from the hospital, a patient meets with a discharge planner who is responsible for helping the patient transition to the next level of care. Depending on the procedures performed, this transition can take weeks, months or years, and in some cases for the remainder of the patient’s life.

When in-home rehabilitation is recommended, the planner would refer the patient to MIT Holding. Through its portfolio of services, MIT Holding then provides its comprehensive medical products through a concierge type service at no additional cost to the patient.

The patient may need a range of services from ambulatory, infusion, durable medical equipment (DME), pharmacy services, improved sanitary spaces, transportation and other recovery services or products. MIT Holding can arrange any or all of these services for the patient. This contractual model creates numerous revenue streams for MIT Holdings along with tremendous cost savings for the patient and insurance company.

“The goal is to provide a non-stressful healing environment possible. The belief is recovery will happen much faster because we meet patients in their home environment, not in a stressful sterile medical facility. The patient completes recovery quicker, insurance company pays less over time creating a win-win situation,” says William Nalley, president of the Orsay Group, Inc., and IR advisor for MIT Holding.

The Affordable Care Act creates pressure for hospitals and doctors to lower costs, and as a result, more people are being discharged earlier from hospitals to reduce the cost of patient care. The cost-saving aspects of MIT Holding’s innovative platform are part of the reason the company believes its business model will be a solid and widespread component of the healthcare industry.

“The Affordable Care Act is a positive for us … one thing it is requiring of hospitals, doctors and medical care in general, is lower prices for services. For the patient, that typically equates to a quicker exit from the hospital or medical facility. We’re the company ¬with our arms open wide saying ‘come to us, we’ll pick up where they left off.’ Imagine if on the last day of your hospital stay you phoned downstairs to the concierge desk and asked: ‘Can you please arrange everything for my home recovery please?’ MIT representatives will come to your room and meet with you to make those arrangements,” Nalley explains.

MIT Holding’s model is an active model. Through its current portfolio of services, the company can arrange for patient pharmaceuticals, intravenous infusions, medical management services, in-home or ambulatory center therapies. The durable medical equipment services (DME) enable the company to offer for sale or rent, home medical equipment, from crutches to hospital beds.

MIT Holding has beta tested its single-source provider concept in Georgia, and to management’s knowledge, is the first to provide this type of comprehensive service within the home medical services industry. The company’s goal is to use its industry-pioneering business model to maintain a number one position in this new industry concept and expand with a nationwide footprint via strategic acquisitions. To achieve this goal a one acquisition per each quarter is the 2015 corporate goal.

“We have the platform for these services in place and we’re ready to duplicate state-by-state,” says MIT Holding chairman and CEO Walter Drakeford. “It’s a tall order to fill, but the company has a clearly defined plan to achieve this mission. The business model is more than gobbling up the first acquisition target to come along. At the core of this precision-based strategy is facility accreditation.”

Accreditation ensures that a facility adheres to certain procedures and guidelines set by each state to insure services and billing are correctly rendered. It’s basically a way to make sure people aren’t opening up companies in the garage of their homes and billing services for deceased patients.

The accreditation process is extremely thorough, taking into consideration various information in 12 different divisions and covering everything from operations to billing, finances and small day-to-day activities. It’s this meticulousness that deters many medical facilities from ever becoming accredited. While it’s not mandatory that facilities become accredited, every supplier of medical equipment has to be accredited to be able to contract with Medicare. Additionally, accreditations must be renewed every two years.

This accreditation is an integral part for MIT Holding’s relationship with its more than 130 insurance provider partners. One of MIT Holding’s affiliates started its accreditation process January 1 to prepare for the June 6, 2015, expiration.

“Preparing for [the accreditation] on the company’s end is something that is time consuming and difficult, but it’s making sure that we have everything in place; which we do,” stated a representative assisting in MIT Holding affiliates accreditation renewal process. “It’s important that the accreditation is passed and every employee is up to par in terms of what the company stands for and what the company requires us to do.”

In fact, if the affiliate had chosen not to renew its accreditation, MIT Holding would have scrapped the partnership; here’s why. The Affordable Care Act does not affect the accreditation process. As such, the accreditation itself has helped legitimately operating companies while unraveling the operations of those that were not.

For example, at one time, the cost of care for patients on oxygen was never capped-out. The insurance company could be billed for the oxygen for as long as the patient lived, whether or not the supplying company ever had contact with the patient. Under the Affordable Care Act, oxygen gets capped out at 36 months. At this point, the supplier has to maintain contact with that patient to make sure they indeed are alive and in need of oxygen. In essence, the Affordable Care Act came in and cleaned house.

“An accreditation sticker on your door shows that you are a reputable company – that you do things beyond the norm in terms of standards. You have had a third party come in and review everything and they have stamped you with a seal of excellence. The accreditation process now has become something that everyone strives to have, not only for insurance reasons but also to show to the community the physicians and the patients that you are a legitimate company upholding the highest patient standards,” says Drakeford.

Here’s where it ties back to MIT Holding. As earlier noted, MIT Holding’s aggressive expansion strategy calls for an acquisition per quarter – however, acquisition or affiliate targets lacking accreditation or not in the process of doing so won’t get a second look from MIT Holding. And it’s been that way for years, according to Drakeford.

“MIT had the foresight two years ago to look at the Affordable Care Act and see the benefits and how to achieve the best results for the company, our patients and our shareholders by adhering to accreditation standards and exemplifying those requirements for anybody we bring on board to duplicate our platform in other states,” he says. “As MIT continues to grow, the affiliations and affiliates that we work with must be accredited. If you’re not professionally respected in your category, you’re not an MIT candidate.”

The company expects that in the next 5 to 10 years it will be mandatory that everyone will be accredited. If true, the requirement would squeeze the number of people that are entering the industry because the standards and expense will be too high. On that note, MIT Holding will be ahead of the game.

“Whether it be on the DME side, the pharmacy side, ambulatory side or infusion side we are seeing certain criteria starting to slowly come into play that in the next 10 years will be factored into whether a company will succeed or fail,” says Drakeford.

MIT Holding plans to duplicate its platform across the U.S. by assembling a portfolio of key affiliates and acquisitions that not only meet accreditation standards, but MIT Holding standards as well.

Among several other criteria, MIT Holding is looking for profitable acquisition targets with a spotless billing history and strong management with an established set of internal controls in place. Accreditation is also a requirement, though companies in the process of accreditation or positioned to initiate the process will be considered. MIT Holding has a few acquisition targets that fit the bill and that are currently undergoing due diligence.

In June, 2014, MIT Holding achieved its first profitable quarter in six years thanks to corporate re-organization initiated in fiscal year 2011. Each MIT Holding subsidiary is now operating with objectives of a 32% net profit. The MIT concept can still deliver services and goods for less than the local medical facility.

Leveraging this improved position, MIT Holding has developed a platform years ahead of its time. As hospitals discharge patients earlier to lower hospital costs, and as accreditation moves toward potential mandate status rather than an option, the company’s strict accreditation policy adds power to its charge at the head of the pack. With patient care in order, MIT Holding is now focusing on shareholder value.

“The accreditation is an example of the height of the demands MIT Holding has on anybody affiliated with the company, which ultimately will reflect through to revenues, shareholder and company valuation,” says Nalley. “We’re now in a position that we can duplicate what’s occurred in Georgia in any other state in the country. MIT makes an acquisition of a facility within that target state, bringing them under our umbrella – and we’re now marketing in that state. Growth of MIT Holding will be the ultimate reward to the shareholder.”

For more information, visit www.mitholdingsinc.com

[QualityStocks]

MITD Introduces New Website with Investor Relations Suite

MIT Holding has announced the launch of a new, redeveloped website possessing an updated, fresh look and improved navigation. The site’s URL is http://mitholdinginc.com.

Developed to support social and commerce platforms which enable discharge planners and patients to set appointments and submit prescriptions, the new web presence also provides its visitors the ability to view a wide selection of medical equipment and supplies, access approved insurance carriers and review charges.

Mr. Tommy J. Duncan, President of MIT Holding commented, “The launch of the updated website and marketing activities, coincide with the ongoing growth and acquisition phase the company is now entering. We have a proven business model that serves as a single source provider of medical concierge services, at no additional charge to the patient. With a successful 9-month beta test in Georgia, our intent is to now duplicate the strategy, state by state, in order to establish a nationwide footprint.”

Running in synch with the new website, MIT Holding has also released a virtual investor relations kit for the purposes of releasing events rapidly. The kit will keep shareholders informed of corporate activities and become increasingly important as the company enters its next phase of acquisition-based growth. The site can be found at http://mitholdinginc.com/resources/MITD_preview.pdf.

MIT Holding offers through its portfolio of licenses, contractual and affiliate agreements a single source provider of medical concierge services and products. Currently including but not limited to; wholesale pharmaceuticals, administer intravenous infusions, medical management services, in home or ambulatory-related therapies. MIT has initiated government contacts to obtain the necessary approvals to import pharmaceutical products into the Americas.

For more information on the company, visit www.mitholdingsinc.com

[QualityStocks]

Updated Fact Sheet is Now Available Online at http://mitd.qualitystocks.net/factsheet

[QualityStocks]

MITD Appoints Tommy J. Duncan to President Role

Earlier today, MIT Holding announced that Tommy J. Duncan is now president of day-to-day operations at MIT Holding. This appointment corresponds with the company’s second phase of corporate re-organization.

“For the last 12 months, MIT Holding has focused on the assembly of a portfolio of licenses, contracts, agreements and working arrangements. Compilation of this portfolio has allowed the company to build, support and begin to offer a ‘one-stop-provider’ of services for patients in transition,” stated Duncan. “The health care system’s continual urging of quicker patient discharges creates an environment in which much of the recovery process and responsibility is forced upon the patient.

“Our goal is to ease this burden and create for patients a single source for all of their necessary medical products and services.”

The new company president will help expand MIT Holding’s offerings while also providing oversight and assistance in dealing with the insurance and government agencies involved in patient recovery costs.

“The expansion of these proven services will continue throughout Georgia as we aggressively begin looking at acquisitions and partnerships to start a nationwide roll-out of services,” commented Duncan.

In addition to his new position as president, Duncan is an independent director at MIT Holding. He previously served as president at Southeast Vending LLC and at Southeast Lumber & Construction, Inc. for which he successfully executed numerous mergers and acquisitions as well as identified and secured financing from multiple funding sources. During his tenures as secretary and treasurer at Auto Locators, Inc. and at Custom Locators USA, Inc., Duncan was recognized for his skills in identifying talented management and hiring them to key positions within each of those companies to accommodate corporate expansion in terms of size and revenues. His prior experience also includes serving on the board of directors at CNB Bancorp, Inc. (Windsor, Virginia).

For more information on MIT Holding, visit www.mitholdingsinc.com

[QualityStocks]

MITD Infuses Itself into the Southern Ambulatory Care Market

Ambulatory care is big business throughout the United States. According to CDC reports, over 136 million visits to emergency rooms and other ambulatory care providers were recorded throughout 2011. Of these visits, over 55 million, or about 40 percent, were reportedly from the southern region of the country. It is in this area that MIT Holding, Inc. (OTCQB: MITD), through its wholly-owned subsidiary, Medical Infusion Technologies, Inc., has been carving a niche into the competitive medical market since 1990.

Medical Infusion Technologies is a trusted provider of outpatient care services servicing a 22-county region ranging from Savannah, GA to Okatie, SC. The company’s primary services include providing ambulatory infusion therapy to patients with conditions requiring ongoing care that doesn’t, necessarily, call for recurring visits to hospitals. The company’s primary care center in Savannah offers patients access to comfortable private infusion suites and a professional medical staff to answer questions and provide needed treatments in a less strenuous environment.

In cases where intravenous medication or nutrient delivery become a recurring part of a patient’s life, the company offers home infusion training and delivery to increase convenience for patients. In this scenario, the company sends a highly trained staff member to equip the patient with the necessary knowledge and medications needed for self-administration of required, recurring medical treatments. Common types of therapies currently available for home infusion include hydration, inotropic therapy, antibiotics, antivirals, antifungals, limited chemotherapy, Synagis® and total parenteral nutrition (TPN).

Other in-home care services offered by the company include a host of perinatal services designed to limit the stresses and complications that can be associated with late-term pregnancy. Care options including pre-term labor, hyperemesis management, diabetes monitoring, hypertension treatment and coagulation disorders are potentially vital treatment capabilities provided to expectant mothers in the comfort of their own homes by MIT Holding, Inc. The company’s large delivery area and knowledgeable staff help recovering patients get the treatment and equipment needed without the stresses commonly associated with hospitals and emergency rooms. With the constantly changing landscape of the healthcare industry, continued evolution and growth initiatives will serve to validate the company’s business model into the future.

For more information on MIT Holding, visit www.mitholdingsinc.com

[QualityStocks]

MITD Engages Investor Relations Services of QualityStocks

Today, MIT Holding announced that QualityStocks has been engaged to provide investor relations services. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value.

“In the last year we’ve primarily focused on a series of transformational achievements, including the revitalization of the MIT Holding business concept and the establishment of new revenue streams to continue profitability,” stated Walter H.C. Drakeford, president of MIT Holding. “Moving into 2015, we anticipate continued success using the QualityStocks network as a catalyst of communication. Our partnership with QualityStocks will enable us to maintain progressive momentum while enhancing shareholder communications and outreach.”

QualityStocks will use its vast network of partners, daily and weekly newsletters, social media channels, blog and other outreach tools to keep existing and potential shareholders informed on MIT Holding’s news and progress while raising the company’s brand visibility among the wider investment community.

“Our communications campaigns, synchronized with the QualityStocks network, are designed to help each client maximize their visibility and shareholder communication initiatives,” stated QualityStocks Managing Director Michael McCarthy. “We look forward to being a part of the company’s growth initiatives as it works to validate its business model among the changing landscape of the healthcare industry.”

For more information on MIT Holding, visit www.mitholdingsinc.com

[Wildbilly]

3rd tier promo

[tradesforyou]

bad 10q, more dilution

[stocktrademan]

bullish

[JesusIsRicher]

should get some eyes on this stock soon. let her fly

[Madkins]

SAVANNAH, GA -- (Marketwired) -- 03/17/14 -- MIT Holding, Inc. (OTCQB: MITD) announces that Coastal Carolina Medical Center has engaged the "Compounding Pharmacy and Infusion Divisions" of MIT Holding Inc., for initial in hospital treatments of patients. These services will then expand in scope and medications. The administration of infusions will become outpatient in a MIT Holding Infusion facility. The average treatment per patient is expected to bill at an average of $923 per treatment.

Walter Drakeford, MITD's CEO, stated, "This ground breaking approach, in addition to offering services in our certified infusion centers, yield significant savings to the hospital while, also offering the same level of service to the patient in a setting absent of the 'hospital stressful' environment. The efficiencies offer to the hospital and convenience for the patient will be a blueprint approach that we would expect our future acquisition targets to emulate."







Mr. Drakeford went on to say; "This contract was structured in a manner that allows for the expansion of additional services and pharmaceuticals as needed and offered to Carolina Coastal."

Management reminds investors and other interested parties of its scheduled conference call, Tuesday, March 18, 2014, at 11:30AM ET, call-in number is #267-507-0240; access code 854127. Log in begins at 11:20 am ET.

About MIT Holding, Inc.

Through its wholly owned subsidiaries, MIT distributes wholesale pharmaceuticals in the United States and overseas, administers intravenous infusions and, in Georgia, operates ambulatory centers where therapies are administered and sells and rents home medical equipment. MIT has initiated government contacts to obtain the necessary approvals to import pharmaceutical products into the Dominican Republic, Haiti, Costa Rica, the Bahamas, Argentina, and Brazil. MIT's domestic wholesale pharmaceutical distribution is conducted through Medical Infusion Technologies, Inc., which sells pharmaceuticals to end-users and other wholesalers in the U.S.

For more information, contact Mr. William Nalley, Orsay Groupe, [e-mail], phone [phone] and/or visit http://www.mitholdingsinc.com/home-2.

Forward-Looking Statements:
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements regarding beliefs, plans, expectations or intentions contain reasonable expectations, but there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.

Add to Digg Bookmark with del.icio.us Add to NewsvineContact:
William NalleyEmail Contact
305-790-2688

http://www.otcdynamics.com/coastal-carolina-medical-center-inc-engages-mit-holding-inc-s-mitd-compounding-pharmacy-and-medical-infusion-technologies-divisions

[ClarkKant]

Looking like a failed promo to me.

[Madkins]

SAVANNAH, GA -- (Marketwired) -- 03/13/14 -- MIT Holding, Inc. (OTCQB: MITD) announces its projected revenues in the first quarter rose 15 percent year over year. The Savannah, GA based holding company estimates 2014 year end revenues of $10 to $15 million with a 30% pretax profit on current and acquired operations.



Walter Drakeford, CEO, stated, "We have worked diligently over the last three years restructuring MITD for growth through acquisitions. With the addition of the CuraSpan contract, and expanded insurance payer business of AmeriGroup, one of the largest health insurers in Georgia, the focus has been shifted to the growth of organic revenues and discussions have begun with several acquisition targets in the South East United States and the greater New York area."





He went on to explain, "MITD is a holding company and at times it can be difficult to understand all of the revenue streams and margins in a Company like ours. We will be conducting a dial-in conference call on Tuesday, March 18, 2014 at 11:30 am ET to fully explain not only our company and revenues, but also our strategy and goals over the next 36 to 48 months."

CONFERENCE Number 267-507-0240, access code 854127, the log in begins at 11:20 am ET and the call will begin at 11:30 am ET.

About MIT Holdings Inc.

For more information, contact Mr. William Nalley, Orsay Groupe, [e-mail], phone [phone] and/or visit http://www.mitholdingsinc.com/home-2.

Forward-Looking Statements:
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements regarding beliefs, plans, expectations or intentions contain reasonable expectations, but there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.

Add to Digg Bookmark with del.icio.us Add to NewsvineContact
William NalleyEmail Contact
305-790-2688

http://www.otcdynamics.com/mit-holding-inc-mitd-earnings-projections-and-dial-in-conference-call-on-tuesday-march-18th-at-1130-am-et

[MoneymakingC]

Promo tomorrow

[Madkins]

SAVANNAH, GA -- (Marketwired) -- 03/11/14 -- MIT Holding, Inc. (OTCQB: MITD) announces that AMGP GEORGIA MANAGED CARE COMPANY, INC., D.B.A. Amerigroup Community Care, revised a "Participating Provider Agreement" to include ambulatory, infusion and perinatal services to the existing "Durable Medical Equipment Contract" (DME). Therefore, the contract will now pay for all services offered by MITD, for a demographically larger range of patients.


AMGP Georgia Managed Care Company, Inc. is a Georgia Care Maintenance Organization (CMO). They serve members in the Georgia Families Programs, such as, Medicaid and PeachCare for Kids. AMGP is dedicated to offering real solutions that improve health care access and quality for its members, while proactively working to reduce the overall cost of care to taxpayers.





Walter Drakeford, MIT Holding, Inc.'s CEO stated, "We've diversified MIT Holding from the beginning as a segmented divisional Company. This structure allows maximum focus for the client's benefit from one division, while maintaining a nimble enough philosophy to add 'overnight' services from our other divisions. In our case, the client can be the patient, the medical facility, or the insurance carrier. AMGP' s decision to expand the existing DME contract to include these additional divisions highlights the success of MITD's market strategy. "

MITD is designed for organic growth, as well as, aggressive acquisition programs. This contract expansion adds an additional layer of service benefits, which significantly increasing MITD's Medicaid billing. Management continues to look for growth strategies which will enhance the Company's revenue streams and shareholder value.

About MIT Holding, Inc.

Through its wholly owned subsidiaries, MIT distributes wholesale pharmaceuticals in the United States and overseas, administers intravenous infusions and, in Georgia, operates ambulatory centers where therapies are administered and sells and rents home medical equipment. MIT has initiated government contacts to obtain the necessary approvals to import pharmaceutical products into the Dominican Republic, Haiti, Costa Rica, the Bahamas, Argentina, and Brazil. MIT's domestic wholesale pharmaceutical distribution is conducted through Medical Infusion Technologies, Inc., which sells pharmaceuticals to end-users and other wholesalers in the U.S.

For more information, contact Mr. William Nalley, Orsay Groupe, [e-mail], phone [phone] and/or visit http://www.mitholdingsinc.com/home-2.

Forward-Looking Statements:
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements regarding beliefs, plans, expectations or intentions contain reasonable expectations, but there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.

Add to Digg Bookmark with del.icio.us Add to NewsvineContact:
William NalleyEmail Contact
305-790-2688

http://www.otcdynamics.com/amgp-georgia-managed-care-company-inc-expands-existing-mit-holding-inc-mitd-contract

[MarkR]

up 42% on good volume, a waste? lol

[StockSleuth]

Watch how this thing tanks. Another company that is stupid enough to pay for a promotion!